

Review

A Fun-Guide to Innate Immune Responses to Fungal Infections

Thomas B. Burgess ^{1,2} , Alison M. Condliffe ² and Philip M. Elks ^{1,2,*} ¹ The Bateson Centre, University of Sheffield, Western Bank, Sheffield S10 2TN, UK; tburgess2@sheffield.ac.uk² Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Beech Hill, Sheffield S10 2RX, UK; a.m.condliffe@sheffield.ac.uk

* Correspondence: p.elks@sheffield.ac.uk; Tel.: +44-(0)-1142-223609

Abstract: Immunocompromised individuals are at high risk of developing severe fungal infections with high mortality rates, while fungal pathogens pose little risk to most healthy people. Poor therapeutic outcomes and growing antifungal resistance pose further challenges for treatments. Identifying specific immunomodulatory mechanisms exploited by fungal pathogens is critical for our understanding of fungal diseases and development of new therapies. A gap currently exists between the large body of literature concerning the innate immune response to fungal infections and the potential manipulation of host immune responses to aid clearance of infection. This review considers the innate immune mechanisms the host deploys to prevent fungal infection and how these mechanisms fail in immunocompromised hosts. Three clinically relevant fungal pathogens (*Candida albicans*, *Cryptococcus* spp. and *Aspergillus* spp.) will be explored. This review will also examine potential mechanisms of targeting the host therapeutically to improve outcomes of fungal infection.

Keywords: fungal infections; antifungal immunity; host–pathogen interaction; immune dysregulation; host-directed therapy



Citation: Burgess, T.B.; Condliffe, A.M.; Elks, P.M. A Fun-Guide to Innate Immune Responses to Fungal Infections. *J. Fungi* **2022**, *8*, 805. <https://doi.org/10.3390/jof8080805>

Academic Editors: Amariliz Rivera, Karen Wozniak and Michal A. Olszewski

Received: 11 July 2022
Accepted: 28 July 2022
Published: 29 July 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Fungal infections are responsible for over 1.7 million deaths per year globally, roughly 200,000 more deaths than the bacterial disease tuberculosis [1], yet the immune responses to fungal infections are much less well studied and understood than those to bacterial infections. Because the burden of fungal diseases is greatest in tropical countries, fungal infections are frequently underfunded [2]. For example, it is estimated that for every individual that dies of bacterial meningococcal meningitis, USD 2458 is spent on research, while only USD 31 is spent per individual that dies of fungal cryptococcal meningitis, despite being responsible for 20 times the number of deaths [3]. Awareness within the general public is low, with less than a third of surveyed Americans being aware of fungal diseases [4].

The severity of fungal disease can range from minor, superficial infections (approximately 1 billion cases worldwide) to severe or life threatening conditions, such as chronic pulmonary aspergillosis (3 million cases worldwide) and severe invasive candidiasis (750,000 cases worldwide) [2]. Severe disease is most common in immunocompromised individuals [5,6]. Major risk factors include comorbidities with HIV/AIDS or tuberculosis, treatments for disease that requires immunomodulation, such as stem cell transplantation, or specific genetic defects resulting in primary immunodeficiency [2,7,8]. Inflammatory conditions such as chronic obstructive pulmonary disease and asthma also predispose patients to fungal infection, but with lower relative risk.

Fungal infections are most commonly treated with antifungal drugs, of which there are three main classes: polyenes, azoles and echinocandins [9]. Because fungi are eukaryotes, identification of specific antifungal targets that do not harm host cells is challenging. Development of new antifungals has been slow, with only 1 antifungal being approved in the last 10 years (isavuconazole, approved in 2015) [10] and so there is a shortage of new

antifungal drugs [11,12]. Increasing antifungal resistance is a compounding issue. In one study of 54 patients across 3 continents, 93% of *Candida auris* patient isolates were resistant to fluconazole, with 41% resistant to 2 antifungal classes and 4% resistant to 3 classes [13]. Antifungal resistant infections are not only emergent, but are deadly. Azole-resistant *Aspergillus fumigatus* prevalence among patients in the Netherlands was 5.3%, but had an 88.0% fatality rate [14]. There is, therefore, a pressing need to develop new treatments for fungal infections.

Fungal spores are ubiquitous in the environment and are encountered on a daily basis [15]. Fungi that enter the body are usually controlled by our innate immune system, preventing disease from developing. Detection of fungal surface ligands by Pattern Recognition Receptors (PRRs) triggers a pro-inflammatory response, resulting in innate immune activation and elimination of fungi when the immune response is effective, or ineffective clearance and development of disease when immunity fails [16–18]. Focussing on 3 clinically relevant fungal pathogens (*Candida albicans*, *Cryptococcus neoformans* and *Aspergillus fumigatus*), this review aims to address the gap between our understanding of innate immunity to fungal infections and the development of novel host-directed strategies to combat infections in patients. The review will consider the role of the innate immune system in responding to fungal infections, how failures of innate immunity can result in severe fungal disease and how the innate immune system could be targeted therapeutically in novel treatments for fungal infections.

2. Innate Immune Control of Fungal Infections

2.1. Barriers to Fungal Entry

The first components of our protection against invading fungi are the physical and anatomical barriers that prevent entry of pathogens, primarily skin and mucosal membranes [17]. The skin is colonised by a range of commensal microorganisms, the main fungal species being members of the *Malassezia* genus [19,20]. Tight junctions in the epithelia form a physical barrier to fungal entry, while *C. albicans* colonisation on the skin has been shown to be controlled by skin-resident dendritic cells [17,21].

The primary mechanism of pulmonary exposure to fungi is inhalation of fungal spores, most commonly *Aspergillus* spp. [22]. Once in the respiratory tract, tight junctions between epithelial cells prevent fungal invasion into the host. A layer of mucus helps trap fungal spores, allowing cilia to move trapped fungi out of the respiratory tract to be coughed up or swallowed into the digestive tract to be destroyed by stomach acid [23].

2.2. Host Recognition of Fungi

Fungal pathogens can circumvent physical barriers and gain entry to the host in the case of a barrier break, e.g., injury. PRRs are able to detect a range of conserved structures on pathogens, known as pathogen associated molecular patterns (PAMPs), as well as detecting the damage caused by pathogens, known as damage associated molecular patterns (DAMPs) [24]. This triggers an intracellular signalling cascade, leading to production of effector proteins and recruitment of innate immune cells (Table 1). There has been a large effort to increase our understanding of PRRs involved in antifungal immunity. C-type lectin receptors (CLRs), such as Dectin-1 and Mincle, are PRRs that have been demonstrated to detect fungi. Dectin-1 specifically detects β -1,3-glucan, a fungal cell wall carbohydrate, stimulating NF- κ B signalling, inflammasome activation, phagocytosis and production of reactive oxygen species (ROS) [25]. Double stranded RNA (a PAMP usually associated with viral infections) in *A. fumigatus* infection is detected by RIG-I-like receptors, which stimulates MDA5/MAVS signalling. Type III interferon expression is entirely reliant on MDA5/MAVS, whereas Type I interferon expression was also triggered through alternative mechanisms [26]. Type III interferon appears to be a critical regulator in neutrophil activation and antifungal immunity [27], suggesting MDA5/MAVS signalling is critical in the antifungal immune response.

Table 1. Pattern recognition receptors in fungal infection.

Pattern Recognition Receptor	Localisation	Cell Expression	Adaptor Proteins	Effectors	Pathogen-/Damage-Associated Molecular Patterns Recognised	Fungal Species	References
TLR2	Plasma membrane	Monocytes, macrophages, dendritic cells, mast cells, neutrophils	MyD88, Mal	NF- κ B, TNF, TGF β , IL-10, IL-12, IFN γ	Phospholipomannan, β -glucans	<i>C. albicans</i> , <i>A. fumigatus</i> , <i>P. brasiliensis</i>	[28–31]
TLR4	Plasma membrane, endosome membrane	Monocytes, macrophages, dendritic cells, mast cells, neutrophils, B cells, intestinal epithelium	MyD88, Mal, TRIF, TRAM	NF- κ B, TNF, IL-8, Type I IFN	O-linked mannosyl, Mannan, Glucuronoxylomannan	<i>C. albicans</i> , <i>A. fumigatus</i>	[28–31]
TLR7	Endosome membrane	Monocytes, macrophages, dendritic cells, B cells	MyD88	IFN- β , Type I IFN	ssRNA	<i>C. albicans</i>	[28,30–32]
TLR9	Endosome membrane	Monocytes, macrophages, dendritic cells, B cells	MyD88	NF- κ B, IL-12, TNF α	Unmethylated DNA with CpG motif	<i>Candida</i> spp., <i>C. neoformans</i> , <i>A. fumigatus</i> , <i>P. brasiliensis</i> , <i>M. furfur</i>	[28,30,31,33,34]
Dectin-1	Plasma membrane	Monocytes, macrophages, dendritic cells, neutrophils, mast cells, some T cells	hemITAM	IL-2, IL-6, IL-10, IL-23	β -1,3-glucans	<i>Candida</i> spp., <i>C. neoformans</i> , <i>A. fumigatus</i> , <i>H. capsulatum</i> , <i>S. cerevisiae</i> , <i>P. brasiliensis</i>	[28,30,31]
Dectin-2	Plasma membrane	Monocytes, macrophages, dendritic cells, neutrophils	ITAM-FcR γ	TNF α	Mannose	<i>C. albicans</i> , <i>C. glabrata</i> , <i>C. neoformans</i> , <i>A. fumigatus</i> , <i>H. capsulatum</i>	[28,30,31]
Mincle	Plasma membrane	Monocytes, macrophages, dendritic cells, neutrophils, mast cells, some B cells	ITAM-FcR γ	NF- κ B, IL-1, IL-6, IL-10, IL-12, IL-23	α -mannose, glyceroglycolipid, mannosyl fatty acids, MSG/gpA	<i>A. fumigatus</i> , <i>C. albicans</i> , <i>P. carinii</i> , <i>Malassezia</i> spp.	[30,31,35]
DC-SIGN	Plasma membrane	Macrophages, dendritic cells, activated B cells	LSP1	IL-10	Mannose, N-linked mannans, galactomannans	<i>C. albicans</i> , <i>C. neoformans</i> , <i>A. fumigatus</i> , <i>S. cerevisiae</i>	[28,30,31]
Mannose Receptor	Plasma membrane	Macrophages, Kupffer cells, endothelial cells	Associated with FcR γ and GBR2, exact mechanism unknown	TNF, IL-1 β	Mannose, α -glucans, chitin	<i>C. albicans</i> , <i>C. neoformans</i> , <i>A. fumigatus</i> , <i>H. capsulatum</i> , <i>S. cerevisiae</i> , <i>P. brasiliensis</i>	[28,30,36,37]
MDA5	Cytoplasm	Monocytes, macrophages, dendritic cells, B cells, epithelial cells, endothelial cells, fibroblasts	CARDs, MAVs	NF- κ B, Type I IFN, Type III IFN, TNF α , IL-12,	dsRNA	<i>C. albicans</i> , <i>A. fumigatus</i>	[26,30]

2.3. Macrophages

Macrophages are a key innate immune cell type in fungal infection control. Recruitment of macrophages to sites of fungal infection is a highly dynamic process. Macrophages cluster around *A. fumigatus* infection in zebrafish and play a role in preventing the yeast-to-hyphae transition, which is associated with increased pathogenicity [38]. The number of macrophages in clusters was highly dynamic, though whether decreases in macrophage density was caused by reverse migration, apoptosis/pyroptosis or cell death was not revealed. In silico analysis of *Mucor circinelloides* infection, supported by observations in zebrafish models of infection, revealed the number of phagocytes present at the site of infection is critical to infection control [39]. The size of macrophage clusters may play a crucial role in control of fungal infections. Resident tissue macrophages have been demonstrated to congregate and “cloak” tissue microlesions with pseudopods in an in vivo mouse sterile injury model, which concealed pro-inflammatory debris, prevented neutrophil swarming and reduced collateral tissue damage caused by neutrophil-mediated inflammation [40]. Though not yet shown in a model of fungal infection, macrophage clustering may similarly facilitate cloaking of damage caused by fungi, limiting the pro-inflammatory neutrophil response and preventing excess tissue damage. Conversely, damage caused by fungi could be too large to effectively cloak, permitting the hyperinflammatory response and collateral tissue damage observed in alternative models of fungal infection [41].

Following recruitment, the primary mechanism of pathogen clearance by macrophages is phagocytosis. Macrophage PRRs or Fc receptors bind to fungal PAMPs or opsonising

antibodies, respectively, triggering engulfment of the fungus [42]. Two mechanisms of fungal engulfment have been described: zipper phagocytosis and coiling phagocytosis (Figure 1) [43,44]. Phagocytosis of *C. neoformans* is typically facilitated by crosslinking of Fc γ receptors and *C. neoformans* bound IgG antibodies. Inability to form lipid rafts with closely localised Fc γ receptors prevents IgG mediated phagocytosis, though complement mediated phagocytosis is unaffected [45]. Following investigation in mouse knockout models, Anion Exchanger 2 has been suggested as a critical regulator of engulfment, through regulation of Dectin-1 expression, and fungal killing, by affecting intracellular pH homeostasis in macrophages [46]. Engulfed fungi are held in the phagosome, which fuses with the lysosome to form a phagolysosome. Acidification of the phagolysosome allows fungal degradation by acid-dependent proteases (such as Cathepsin D), combined with fungal killing by ROS and reactive nitrogen species (RNS) [42,47,48]. Hatinguais et al., demonstrated mitochondrial ROS, produced via reverse electron transport, not only contribute to the destruction of phagocytosed *A. fumigatus* conidia, but also trigger production of TNF- α and IL-1 β in vitro, stimulating further antifungal responses [49]. Although inhibition of mitochondrial H₂O₂ impaired phagocytosis of *A. fumigatus* by alveolar macrophages in a mouse model, neutrophil activity was not impaired and survival and fungal burden were not affected [50]. Hence, while mitochondrial ROS are important in for the antifungal activity of alveolar macrophages, NADPH oxidase activity is able to compensate effectively, displaying redundancy in the host antifungal response. While lysosomal degradation is the typical outcome of phagocytosis, macrophage-to-macrophage transfer (termed “Dragocytosis”) of *C. neoformans* has also been observed in vitro [51]. Shah et al., observed a similar phenomenon in *A. fumigatus* infection. Hyphal growth of phagocytosed *A. fumigatus* caused macrophage necrosis, triggering macrophage-to-macrophage transfer of germinating *A. fumigatus*, preventing fungal escape [52]. Unlike dragocytosis, transfer of *A. fumigatus* was macrophage necrosis-dependent. However, the biological significance of these phenomena is unknown. Vomocytosis (also referred to as nonlytic exocytosis) is the expulsion of phagocytosed particles without degradation into the extracellular environment and occurs in macrophages in vitro during *C. albicans* and *C. neoformans* infection [53,54]. In mammalian in vitro and zebrafish in vivo models of cryptococcosis, vomocytosis is regulated by the MAP kinase ERK5. Viral infection and type I interferon signalling have been associated with enhanced rates of vomocytosis in vitro [55,56]. It is possible that the expulsion phase of dragocytosis operates by a similar mechanism.

Phagocytosis of fungi is not always possible: *C. albicans* and *A. fumigatus* hyphae may become too long to phagocytose and *Cryptococcus neoformans* titan cells are too large to phagocytose [57–59]. Inability to phagocytose a pathogen typically leads to frustrated phagocytosis, a process in which there is downregulation of phagocytosis mechanisms and a strong inflammatory response mediated by IL-1 β [60,61].

Phagocytosis of *C. albicans* can trigger a yeast-to-hyphae transition, leading to macrophage killing through mechanical piercing by hyphae or induction of pyroptosis, allowing escape of *C. albicans* [62]. To counteract this, macrophages are able to fold phagocytosed fungal hyphae at septal junctions (Figure 1), resulting in significantly reduced hyphal growth and disruption to the cell wall [63]. Exactly how much hyphal folding contributes to fungal clearance is unknown, however, this represents a previously uncharacterised macrophage function, which may be relevant to other hyphal pathogens.

Macrophages are a highly heterogenous population, existing on a spectrum of behaviours between M1, pro-inflammatory phenotypes and M2, wound healing phenotypes [64]. Proteomic analysis revealed a pro-inflammatory to wound healing phenotypic switch in *C. albicans* infection, whereas *C. neoformans* infection drives macrophages into a naïve M0 phenotype [65,66]. Stimulating an M1 phenotype led to decreased fungal burden and increased survival of mouse models in *C. albicans* and *C. neoformans* infection [67,68]. Promotion of an M2 phenotype in *A. fumigatus* infection reduces control of infection, corresponding with the other fungal pathogens [69]. This reveals a mechanism to avert pro-inflammatory macrophage polarisation to the detriment of the host, driven

by immunosuppressive drugs (e.g., steroids) or interactions with fungal pathogens. It could be possible to improve outcomes of fungal infection by therapeutically promoting M1 macrophage polarisation, though this must be done with caution to prevent excess, harmful inflammation.




Figure 1. Cellular Innate Immune Control of Fungal Infections. Various mechanisms exist for the control of fungal infections by the innate immune system. Macrophages phagocytose fungi, undergo macrophage clustering or fold phagocytosed hyphae. Recognition of fungal ligands, such as candidalysin, stimulates production of IL-1 β , triggering neutrophil recruitment [70]. Increased expression of IL-33 in *C. albicans* infection triggers neutrophil recruitment and phagocytosis [71]. Neutrophils may also release reactive oxygen species (ROS) or neutrophil extracellular traps, degranulate, phagocytose fungi or undergo swarming. Eosinophils have antifungal effects through degranulation [72] and production of IL-17, which stimulates pro-inflammatory signalling, production of antimicrobial peptides and Th17 cell differentiation [73,74].

2.4. Neutrophils

Neutrophil recruitment to fungi, like macrophages, is driven by detection of PAMP/DAMPs by PRRs (Table 1). Mincle binds α -mannose and other fungal cell wall components, resulting in pro-inflammatory signalling and recruitment of neutrophils [30,75]. RIG-I-like receptor detection of double stranded RNA stimulates a strong neutrophil-mediated antifungal response via MDA5/MAVS signalling [26,27]. Candidalysin, produced by hyphal *C. albicans*, appears to be a potent stimulator of innate immune responses in mucosal, central nervous system and systemic infections [70,76,77]. Candidalysin stimulates IL-1 β production via a CARD9-dependent mechanism, which in turn leads to CXCL1-mediated recruitment of neutrophils [70]. TRAF1 (induced by the pro-inflammatory cytokine TNF) inhibits CXCL1 in *C. albicans* infection [78,79], suggesting a regulatory role for TRAF1 to prevent excess neutrophil recruitment and activation. Epidermal growth factor receptor (EGFR) may also be key for immune responses to candidalysin. Inhibition of EGFR in mouse models of oral candidiasis reduces IL-1 β and CXCL1 [80,81], suggesting EGFR may be the initial receptor responsible for CXCL1-mediated neutrophil recruitment. Neutrophil recruitment and survival are also reduced by EGFR inhibition, providing strong evidence of the link between candidalysin, EGFR and CXCL1-mediated neutrophil recruitment. IL-33 is another key mediator of neutrophil recruitment [82] and IL-33 knockout mice

have increased mortality in *C. albicans* infection. Based on in vitro primary cell models, IL-33 operates via IL-23 and GM-CSF to promote phagocytosis by neutrophils [71]. IL-33 also suppresses IL-10 expression, resulting in superior fungicidal activity by neutrophils in vitro. IL-10 expression has been associated with persistent *C. albicans* infection in other in vitro data [83], which may be due to reduced neutrophil activity. IL-23 has additional mechanisms of aiding antifungal immunity. IL-23 deficient mice have increased myeloid cell apoptosis, resulting in reduced survival in systemic *C. albicans* infection [84]. Interestingly, this occurred independent of IL-17 and was unique to fungal infections.

Neutrophils have been shown to coordinate their migration to sites of infection through a process called neutrophil swarming [85]. Swarming inhibits the growth of several fungal pathogens in vitro: *C. albicans*, *C. auris*, *Candida glabrata*, *C. neoformans* and *A. fumigatus* [86–88]. Swarms were smaller for yeast-locked *C. albicans*, *C. auris* and *C. glabrata* (which are unable to hyphate) compared to wild type *C. albicans* [87]. Furthermore, using an in vitro model of *A. fumigatus* infection, swarms appeared to preferentially form around hyphae [88]. This implies a potential correlation between hyphae formation and neutrophil swarming, which requires further investigation. Swarming in fungal infections is dependent on LTB₄, meaning it operates by the same mechanism as swarming in other infections or injury [86,89,90].

Following migration to sites of infection, neutrophils have several mechanisms to eliminate fungal pathogens, including phagocytosis and degradation in the phagolysosome, degranulation, production of ROS and neutrophil extracellular trap (NET) release (Figure 1). Neutrophils produce granules containing a range of bactericidal and fungicidal effectors, including myeloperoxidase, cathepsins, defensins and lactoferrin [91]. The secretion of effectors in degranulation leads to fungal killing and is preferentially used in *Candida* infections with pseudo-hyphae [92]. Degranulation was dependent on CXCR1 in *C. albicans* infection in a mouse model, demonstrating a novel function of murine CXCR1 which correlates with evidence that human CXCR1 promotes oxidative and non-oxidative bactericidal activity by neutrophils [93,94]. Neutrophils also produce ROS, such as superoxide or hydrogen peroxide, which can be used intracellularly to kill phagocytosed fungi, or extracellularly to target hyphae [95,96]. Neutrophils are capable of expelling chromatin covered in antimicrobial proteins, leading to entrapment and killing of extracellular pathogens [97]. These neutrophil extracellular traps (NETs; Figure 1) are host protective against *C. albicans*, *Cryptococcus neoformans* and *Aspergillus nidulans* in in vitro human neutrophil models [87,97–99] and may be involved in swarm initiation [87,100]. NETs have also been demonstrated to directly stimulate Th17 cell differentiation, via TLR2 and ROR γ t, corresponding with increasing IL-17 and GM-CSF production [101]. IL-17 and GM-CSF both stimulate neutrophil activity in fungal infection [71,102], creating a feedback loop, in which NETs promote an adaptive immune response and additional neutrophil activity. A subpopulation of neutrophils also produce IL-17, which may further feed into this positive feedback loop [103]. Recent evidence suggests NETosis induced by *C. albicans* can occur independent of Peptidylarginine deiminase 4 (PAD4), contradicting established literature that NETosis is PAD4-dependent [104–107]. Alternative studies demonstrated PAD4 is not necessary for NET formation or neutrophil-mediated control of *A. fumigatus* infection [108,109]. Further research is needed to clarify whether PAD4-independent NETosis is a non-canonical mechanism of NETosis for all stimuli or is a phenomenon unique to fungal infections. Despite their fungicidal role, NETs may have an overall detrimental effect on the host. NET proteins intended to eliminate fungi have been observed bound to, but not killing, *C. albicans* and inducing apoptosis of host cells [110]. Furthermore, inhibition of NETosis reduced *A. fumigatus* burden in mouse models of invasive pulmonary aspergillosis [111]. However, these experiments inhibited NETosis by generating PAD4 knockout mice, which does not account for the possibility of PAD4-independent NETosis. Alternative methods of NETosis inhibition may be required to provide greater support to these conclusions.

Transfer of phagocytosed *A. fumigatus* conidia from neutrophils to macrophages by a β -glucan dependent mechanism has been observed in zebrafish [112]. The function of shuttling, and significance in fungal clearance, remains unclear, with conflicting arguments stating shuttling is a fungal strategy to avoid degradation by neutrophils or that shuttling is a host strategy to facilitate antigen presentation and initiate adaptive immune responses [38,112].

2.5. Other Innate Immune Components of Fungal Protection

Though typically associated with allergic disease, eosinophils can detect and respond to fungal infection, primarily through degranulation [72,113]. In a mouse model of acute *A. fumigatus* infection, eosinophils expressed ROR γ t, IL-23R and IL-17, which all have pro-inflammatory functions [73]. Increased IL-17 expression also occurred independent of IL-23 signalling, suggesting *A. fumigatus* promotes IL-17 production by eosinophils by an unknown mechanism. The pro-inflammatory IL-17 phenotype helps to protect against *A. fumigatus* infection (Figure 1), but is also responsible for tissue damage and lung pathology [73,74]. Eosinophils play a dichotomous role in fungal infection, whereby they both protect and damage the host.

Innate lymphoid cells (ILCs) are a rapidly emerging area of research. In a mouse model of oropharyngeal candidiasis, ILCs in the oral mucosa were the primary source of pro-inflammatory IL-17 during *C. albicans* infection, acting as the first line of defence in the antifungal response. Depletion of ILCs increased susceptibility to *C. albicans* infection, with increased fungal burden and greater reduction in body weight [114]. 3 distinct ILC subpopulations have been identified. Type 3 ILCs (ILC3s) in acute *A. fumigatus* lung infection in mice produce IL-22, a critical cytokine for clearance of *A. fumigatus* [115]. Stimulation of ILC3s by cytokines in vitro or *Citrobacter rodentium* infection in vivo resulted in stabilisation of HIF-1 α , inducing glycolysis and ROR γ t production. Activation of ILC3s, characterised by secretion of IL-17 and IL-22, is also dependent on production of mitochondrial ROS, which aids HIF-1 α and ROR γ t stabilisation [116]. Validation of this mechanism following stimulation with fungal pathogens is required.

Complement has previously been demonstrated to be crucial in responses to fungal infection, with complement-deficient mouse and guinea pig models being more vulnerable to *Candida* infections [117,118]. CD11b (also called CR3) is a common β subunit of β 2 integrin complement receptors. While survival is not affected, CD11b knockout mice have reduced pro-inflammatory cytokines and reduced phagocytic activity by neutrophils during *A. fumigatus* infection but enhanced neutrophil infiltration [119]. Hence, complement activation of CD11b may be vital for triggering phagocytosis but plays no role in neutrophil recruitment. CR3 can also bind to β -glucan, triggering phagocytosis of β -glucan-bearing particles [120,121]. Binding of CR3 to β -glucan in *C. albicans* infection initiates a complex, temporally regulated pathway that can differentially upregulate neutrophil swarming and NETosis [122]. Inhibition of CR3 during in vitro *A. fumigatus* infection reduced production of IL-8 and MCP-1 and reduced activation of NF- κ B, demonstrating CR3 has a role in mediating release of pro-inflammatory cytokines in *A. fumigatus* infection [123]. Together these studies reveal CR3 to be a complex, multifaceted protein, with important antifungal roles beyond the complement cascade.

3. Failures of Innate Immunity in Disease

3.1. *Candida albicans*

While usually a commensal fungus, commonly colonising the gastrointestinal and genitourinary tracts of most humans, *C. albicans* is also an opportunistic pathogen [124,125]. Immunocompromised patients are most at risk of candidiasis, whether their immune defects are caused by HIV/AIDS, immunosuppressive drugs, old age or genetic disorders [126]. Chronic mucocutaneous candidiasis (CMC) is recurrent or persistent infections of mucosal membranes caused by *Candida* species, primarily by *C. albicans* [127]. Severity of CMC is highly variable and dependent on the anatomical location of *C. albicans* infection:

from soreness around the mouth and ulceration in oral cavity infections to abdominal pain and severe diarrhoea in digestive tract infections [128]. Although progression of CMC to systemic candidiasis is relatively rare, acquisition of invasive candidiasis in intensive care units is fairly common (7.07 episodes per 1000 admissions) and has a 42% 30-day mortality [129].

Susceptibility to recurrent *Candida* infection in CMC is caused by various host genetic mutations, the most common being STAT1 gain of function mutations [130]. These mutations increase STAT1 responses to IFN α , IFN β , IFN γ and IL-27, causing repressed development of IL-17 T cells and susceptibility to mucosal *Candida* infection [131]. An alternative genetic mutation underlying CMC is autosomal recessive CARD9 deficiency [132]. CARD9 is an adaptor protein utilised by a variety of CLRs, such as Dectin-1, to stimulate NF- κ B signalling. CARD9 deficiency has been demonstrated to cause reduced cytokine production by human patient peripheral blood mononuclear cells and impaired neutrophil recruitment in in vivo mouse models, leading to increased susceptibility to systemic candidiasis [133,134]. While several mutant CARD9 alleles associated with CARD9 deficiency have been revealed [132], less established is the effect other gene mutations may have on CARD9 expression. Ovarian tumour deubiquitinase family member 1 (OTUD1) has recently been identified as a positive regulator of CARD9. OTUD1 deubiquitinates ubiquitinated CARD9, leading to CARD9 activation. Infection of OTUD1 homozygous knockout mice with *C. albicans* led to reduced mouse survival and increased fungal burden in kidney, lung and spleen slices compared to wild type mice [135]. OTUD1 mutations may cause susceptibility to *C. albicans* infection through CARD9 deficiency (Figure 2), highlighting a novel cause of CMC and introducing a potential therapeutic target for treatment of CARD9 deficiency.

Given its key role in NF- κ B signalling, MyD88 defects have been associated with susceptibility to a range of infectious diseases [136]. MyD88 knockout mice are highly susceptible to *C. albicans* infection, with increased mortality and fungal burden [137]. In a zebrafish wound model, MyD88 deficiency caused reduced recruitment of both local and distant neutrophils, which was maintained over 6 hours [138]. MyD88 deficiency, however, did not impair neutrophil activation, which was dependent on MAVS signalling. Although only studied in a wound model, if this mechanism is maintained in fungal infection, it would suggest patients with MyD88 deficiency have impaired neutrophil recruitment (but no defects in neutrophil activation), which causes increased susceptibility to *C. albicans* infection (Figure 2).

IL-17 is a key regulator of antifungal immunity. IL-17 knockout mice have high susceptibility to *C. albicans* infection and reduced levels of neutrophil-recruiting chemokines [139,140]. A strong association has been demonstrated between candidiasis and use of IL-17 inhibitors (used in treatment of several inflammatory diseases), with significant downregulation of 9 pro-inflammatory cytokines or neutrophil-recruiting chemokines [141]. A recent clinical study demonstrated 16 CMC patients had lower serum IL-17 levels than healthy controls [142], supporting previous evidence that IL-17 is impaired in CMC patients [143]. IL-17 defects have been attributed to STAT1 gain of function mutations, IL-17 mutations and anti-IL-17 autoantibodies [143–146].




Figure 2. Failures of innate immunity in fungal infection. Examples of specific failures of innate immunity which lead to susceptibility to fungal infection. STAT1 gain of function mutations increase sensitivity to IFNs, leading to increased susceptibility to fungal infections [131]. OTUD1 or MyD88 deficiencies result in reduced transcription of NF-κB, resulting in reduced inflammatory response and increased *C. albicans* burden [135,138]. CARD9 deficiency causes reduced NF-κB transcription, resulting in reduced inflammatory response and increased *A. fumigatus* burden [147]. NADPH oxidase deficiency in CGD patients reduced production of ROS, reducing the ability to kill *A. fumigatus* and removing ROS-mediated inhibition of NF-κB, resulting in excess TNF production and host injury [41,131]. Anti-GM-CSF antibodies prevent macrophage differentiation and activation, resulting in inability to control *C. neoformans* infection [148].

3.2. *Cryptococcus spp.*

Cryptococcosis, caused by *Cryptococcus spp.*, is a global issue, causing roughly 181,000 deaths annually worldwide and being responsible for 15% of all AIDS-related deaths [149,150]. Risk factors, other than HIV infection, include diabetes mellitus, cirrhosis, blood disorders or prolonged immunosuppression [131]. Cryptococcal infections typically begin in the lungs then disseminate to cause infections in the central nervous system, either as free yeasts or inside ‘trojan horse’ phagocytic cells [151]. *Cryptococcus neoformans* is the primary cause of cryptococcosis but *Cryptococcus gattii* is a rapidly emerging species, capable of causing infection in immunocompetent individuals, with a serious outbreak in the 2000s in Vancouver Island, Canada [152,153]. Unlike other pathogenic fungi, *Cryptococcus spp.* are yeast-locked and do not form hyphae during infection [154].

A number of patients with cryptococcosis have presented with anti-GM-CSF autoantibodies [155–157]. GM-CSF autoantibodies have previously been linked to pulmonary alveolar proteinosis, a rare condition affecting the ability of alveolar macrophages to remove excess surfactant, demonstrating an association between GM-CSF deficiency and macrophage function [147,158]. More recent investigations show impaired activation of macrophages in GM-CSF knockout mice with cryptococcal lung infection. Furthermore, GM-CSF deficiency in these mice reduced the differentiation and maturation of Ly-6C monocytes (macrophage precursor cells) into mature alveolar macrophages [148]. Therefore, cryptococcosis in patients with anti-GM-CSF autoantibodies may be caused by reduced levels of mature alveolar macrophages and an inability to activate these macrophages (Figure 2).

3.3. *Aspergillus* spp.

Infections caused by *Aspergillus* spp. most commonly occur in the lower respiratory tract or lungs [159]. *A. fumigatus* is the second most common cause of fungal infections in hospitalised patients, behind *C. albicans* [160]. *Aspergillus* infection is responsible for a range of severe pulmonary diseases, including: invasive pulmonary aspergillosis, chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis [160]. Besides causing irreversible lung damage, these conditions can also lead to systemic aspergillosis.

Stem cell transplants (SCTs; used in treatment of some cancers and blood disorders) are a major risk factor for *Aspergillus* infection. 9.3% of SCT recipients develop invasive fungal disease, most frequently caused by *Aspergillus* spp., resulting in 70.8% mortality 1 year post diagnosis of fungal infection [161]. Following a SCT, patients are profoundly cytopenic while the immune system recovers and often receive additional immune suppression to prevent graft vs. host disease [162]. This cytopenia leads to the extreme vulnerability to fungal infection.

Aspergillus infection is particularly common in patients with chronic granulomatous disease (CGD). CGD results from defective NADPH oxidase complexes in phagocytes, leading to an inability to produce ROS [131]. Consequently, CGD patients are less able to kill pathogens so are highly susceptible to *Aspergillus* infection. Cagnina et al., recently showed excess TNF production in a CGD mouse model challenged with *Aspergillus* triggers additional neutrophil recruitment, driving a pro-inflammatory spiral which is responsible for host lung damage [41]. This supports other research demonstrating exaggerated TNF responses are responsible for host injury [163,164]. ROS are believed to inhibit NF- κ B signalling to prevent hyper-inflammation [165,166]. Inability to produce ROS in CGD patients eliminates ROS-mediated NF- κ B inhibition, resulting in a hyperinflammatory environment and host injury (Figure 2).

Although mainly associated with candidiasis, CARD9 deficiency is increasingly being linked to susceptibility to a wider range of fungal infections, including *Aspergillus* [132,167]. CARD9 deficiency caused far greater increases in mortality in mice during *C. albicans* infection compared to *A. fumigatus* infection [134,168], suggesting CARD9 exhibits some redundancy in control of *Aspergillus*.

4. Host-Directed Therapies

There are many issues concerning current antifungal treatment: toxicity of antifungals, low effectiveness, slow development of new antifungals and the rise of antifungal resistance [169]. A potential alternative strategy to treating infectious disease is therapeutic targeting of the immune system, an approach that should be more resilient against emerging drug resistance. Host-directed therapies (HDTs) stimulate host cellular pathways and activate immune responses to aid clearance of pathogens [170]. HDTs have been proposed as an adjunctive therapy alongside current antifungals [171].

Some HDTs function by promoting increased immune cell production or recruitment, to bolster the innate immune response. G-CSF is an endogenous signalling molecule that induces formation of granulocyte precursor cells, which will later differentiate into mature neutrophils. GM-CSF has a similar role in immune cell development, but with a wider spectrum of activity [172,173]. G-CSF/GM-CSF treatment aids clearance of *C. albicans* and *A. fumigatus* in *in vitro* models and *in vivo* rabbit and mouse models [174–176]. In two separate cases of relapsing *C. albicans* meningoencephalitis in CARD9-deficient patients, treatment with either G-CSF or GM-CSF resulted in complete clinical remission [177,178]. In another case, a paediatric patient with a history of CMC and CARD9 deficiency was successfully treated for invasive *C. albicans* infection by a combination of G-CSF and antifungals [179]. The primary mechanism believed to underly G-CSF/GM-CSF treatment is increased production, maturation, proliferation and activation of neutrophils, macrophages, monocytes and eosinophils [180]. However, G-CSF/GM-CSF have also been suggested to modulate immune activity by stimulating pro-inflammatory cytokine production, phagocytosis and ROS production, though this is based on *in vitro* evidence and may not be

observed in human fungal infections [181–184]. Therefore, G-CSF/GM-CSF shows potential for treating *C. albicans* and *A. fumigatus* infections in immunodeficient patients. Targeting spleen tyrosine kinase (syk) was suggested as a potential HDT after syk was shown to be critical for protection against *C. albicans* infection in mice models, through regulation of neutrophil responses [185,186]. Syk is a downstream signalling molecule of several fungal PRRs, such as Dectin-1 [185,187], meaning syk is critical for the initial recognition of fungal infection, as well as neutrophil swarming, phagocytosis, NETosis and ROS production. However, while syk inhibitors have been developed and approved for clinical use [188], to the best of our knowledge, there are currently no pharmacological syk stimulators for experimental or clinical use, introducing significant barriers to further investigation of syk as a potential HDT. Rhesus theta defensin-1 (RTD-1) is an antimicrobial peptide, with potent antifungal properties in both in vitro and in vivo mouse models. RTD-1 also promotes neutrophil recruitment and reduces TNF, IL-1 β and IL-17 production in *C. albicans* infected mice [189,190]. Furthermore, RTD-1 suppresses pro-inflammatory cytokines in in vitro and in vivo mouse models, reducing host damage, improving long term outcomes and improving pathogen clearance [191–194]. Hence, RTD-1 represents a promising new class of therapy, capable of modulating host responses to improve long term outcomes to infection, while also having a direct antifungal effect.

HDTs may also modulate innate immune cell responses, to improve their fungicidal activity. Following successful clinical trials, interferon gamma (IFN γ) is already used as a HDT as an antifungal prophylaxis and halves the occurrence of acute *Aspergillus* infection in CGD patients [195–197]. IFN γ stimulates increased ROS production by granulocytes, as well as promoting Th1 responses and enhanced macrophage activity [198,199]. Recent evidence has suggested IFN γ production is impaired in patients with chronic pulmonary aspergillosis, suggesting IFN γ therapy may also be beneficial in these patients [200]. Another potential HDT is HIF-1 α (Hypoxia Inducible Factor) stabilisation. Hif-1 α stabilisation is protective against *Mycobacterium marinum* infection in zebrafish larvae via IL-1 β , which stimulates antimicrobial nitric oxide production [201,202]. In addition, Hif-1 α deficient mice have been shown to be more susceptible to *C. albicans* infection [203]. Hif-1 α stabilisation has potential as a HDT for treatment of fungal infections but requires appropriate in vitro models that allow both genotypic and phenotypic characterisation of the effects of Hif-1 α stabilisation on fungal infection and immune cell behaviour.

An emerging HDT opportunity in fungal diseases is an increased understanding of trained innate immunity, where innate immune cells exhibit long-term adaptive characteristics after immune challenge [204]. Much of the research in this area has focused on training immunity with bacterial products, such as lipopolysaccharide (LPS) or bacillus Calmette-Guérin vaccine (BCG) that can trigger different trained immunity programmes that protect against subsequent infections [205]. However, some of the earliest demonstrated examples of trained immunity were in murine studies using low-dose *Candida* spp infection in T- and B-cell depleted animals, that showed protection against a subsequent lethal dose of fungal infection [206]. The fungal cell wall component β -glucan was sufficient to provide trained innate immunity protection and this response was dependent on functional circulating monocytes [206]. There is emerging evidence that challenge with avirulent *Candida* spp can provide protection against sepsis caused by bloodstream fungal infections, with a potential role for GR-1⁺ putative myeloid-derived suppressor cells (MDSCs) [207,208]. These findings open up the possibility of using trained immunity to treat fungal infections, but there is more to understand on the exact mechanisms, programmes and specificity of fungal-induced trained immunity before potential exploitation in the clinic [209].

5. Conclusions

From established processes, such as phagocytosis and production of ROS, to recently discovered phenomena, such as hyphal folding, the innate immune system is critical in host immune responses to fungal infections. The fact that new mechanisms are still being uncovered highlights the complexity of the innate response. However, many questions

remain unanswered. It remains to be seen how clinically significant recent observations from in vitro/ex vivo experiments are, for example, NET release, fungal shuttling and hyphal folding. The ability to unravel these questions relies on in vivo models for fungal infections, which are translatable to human disease and immune responses. These models are also vital to understand mechanisms underlying increased vulnerability to fungal infections in immunocompromised individuals and the effects of HDTs on fungal clearance and immune cell behaviour.

Author Contributions: Conceptualization, T.B.B., A.M.C. and P.M.E.; writing—original draft preparation, T.B.B., A.M.C. and P.M.E.; writing—review and editing, T.B.B., A.M.C. and P.M.E.; supervision, A.M.C. and P.M.E.; funding acquisition, P.M.E. All authors have read and agreed to the published version of the manuscript.

Funding: P.M.E. is funded by a Sir Henry Dale Fellowship, jointly funded by the Wellcome Trust and the Royal Society (Grant Number 105570/Z/14/A) held by P.M.E. T.B.B. is supported by a studentship from the MRC Discovery Medicine North (DiMeN) Doctoral Training Partnership (MR/N013840/1). For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kainz, K.; Bauer, M.A.; Madeo, F.; Carmona-Gutierrez, D. Fungal Infections in Humans: The Silent Crisis. *Microb. Cell* **2020**, *7*, 143–145. [[CrossRef](#)] [[PubMed](#)]
2. Bongomin, F.; Gago, S.; Oladele, R.; Denning, D. Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision. *J. Fungi* **2017**, *3*, 57. [[CrossRef](#)] [[PubMed](#)]
3. Rodrigues, M.L.; Albuquerque, P.C. Searching for a Change: The Need for Increased Support for Public Health and Research on Fungal Diseases. *PLoS Negl. Trop. Dis.* **2018**, *12*, e0006479. [[CrossRef](#)] [[PubMed](#)]
4. Benedict, K.; Molinari, N.A.M.; Jackson, B.R. Public Awareness of Invasive Fungal Diseases—United States, 2019. *Morb. Mortal. Wkly. Rep.* **2020**, *69*, 1343. [[CrossRef](#)]
5. Enoch, D.A.; Yang, H.; Aliyu, S.H.; Micallef, C. The Changing Epidemiology of Invasive Fungal Infections. *Methods Mol. Biol.* **2017**, *1508*, 17–65. [[CrossRef](#)]
6. Friedman, D.Z.P.; Schwartz, I.S. Emerging Fungal Infections: New Patients, New Patterns, and New Pathogens. *J. Fungi* **2019**, *5*, 67. [[CrossRef](#)]
7. Shi, J.; Pei, X.; Luo, Y.; Tan, Y.; Tie, R.; He, J.; Zheng, W.; Zhang, J.; Cai, Z.; Lin, M.; et al. Invasive Fungal Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Single Center Experiences of 12 Years. *J. Zhejiang Univ. Sci. B* **2015**, *16*, 796–804. [[CrossRef](#)]
8. Maskarinec, S.A.; Johnson, M.D.; Perfect, J.R. Genetic Susceptibility to Fungal Infections: What Is in the Genes? *Curr. Clin. Microbiol. Rep.* **2016**, *3*, 81–91. [[CrossRef](#)]
9. Chang, Y.-L.; Yu, S.-J.; Heitman, J.; Wellington, M.; Chen, Y.-L. New Facets of Antifungal Therapy. *Virulence* **2017**, *8*, 222–236. [[CrossRef](#)]
10. Daele, R.V.; Spriet, I.; Wauters, J.; Maertens, J.; Mercier, T.; Hecke, S.V.; Brüggemann, R. Antifungal Drugs: What Brings the Future? *Med. Mycol.* **2019**, *57*, S328–S343. [[CrossRef](#)]
11. Perfect, J.R. The Antifungal Pipeline: A Reality Check. *Nat. Rev. Drug Discov.* **2017**, *16*, 603–616. [[CrossRef](#)]
12. Rauseo, A.M.; Coler-Reilly, A.; Larson, L.; Spec, A. Hope on the Horizon: Novel Fungal Treatments in Development. *Open Forum Infect. Dis.* **2020**, *7*, ofaa016. [[CrossRef](#)]
13. Lockhart, S.R.; Etienne, K.A.; Vallabhaneni, S.; Farooqi, J.; Chowdhary, A.; Govender, N.P.; Colombo, A.L.; Calvo, B.; Cuomo, C.A.; Desjardins, C.A.; et al. Simultaneous Emergence of Multidrug-Resistant *Candida Auris* on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. *Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.* **2017**, *64*, 134–140. [[CrossRef](#)]
14. van der Linden, J.W.M.; Snelders, E.; Kampinga, G.A.; Rijnders, B.J.A.; Mattsson, E.; Debets-Ossenkopp, Y.J.; Van Tiel, F.H.; Melchers, W.J.G.; Verweij, P.E. Clinical Implications of Azole Resistance in *Aspergillus Fumigatus*, the Netherlands, 2007–2009. *Emerg. Infect. Dis.* **2011**, *17*, 1846–1854. [[CrossRef](#)]
15. Hernandez, H.; Martinez, L.R. Relationship of Environmental Disturbances and the Infectious Potential of Fungi. *Microbiology* **2018**, *164*, 233–241. [[CrossRef](#)]

16. Figueiredo, R.; Carneiro, L.; Bozza, M. Fungal Surface and Innate Immune Recognition of Filamentous Fungi. *Front. Microbiol.* **2011**, *2*, 248. [[CrossRef](#)]
17. Drummond, R.A.; Gaffen, S.L.; Hise, A.G.; Brown, G.D. Innate Defense against Fungal Pathogens. *Cold Spring Harb. Perspect. Med.* **2015**, *5*, a019620. [[CrossRef](#)]
18. Heung, L.J. Monocytes and the Host Response to Fungal Pathogens. *Front. Cell. Infect. Microbiol.* **2020**, *10*, 34. [[CrossRef](#)]
19. Findley, K.; Oh, J.; Yang, J.; Conlan, S.; Deming, C.; Meyer, J.A.; Schoenfeld, D.; Nomicos, E.; Park, M.; Kong, H.H.; et al. Human Skin Fungal Diversity. *Nature* **2013**, *498*, 367–370. [[CrossRef](#)]
20. de Hoog, S.; Monod, M.; Dawson, T.; Boekhout, T.; Mayser, P.; Gräser, Y. Skin Fungi from Colonization to Infection. *Microbiol. Spectr.* **2017**, *5*, 5.4.05. [[CrossRef](#)]
21. Igyártó, B.Z.; Haley, K.; Ortner, D.; Bobr, A.; Gerami-Nejad, M.; Edelson, B.T.; Zurawski, S.M.; Malissen, B.; Zurawski, G.; Berman, J.; et al. Skin-Resident Murine Dendritic Cell Subsets Promote Distinct and Opposing Antigen-Specific T Helper Cell Responses. *Immunity* **2011**, *35*, 260–272. [[CrossRef](#)]
22. Hamilos, D.L. Allergic Fungal Rhinitis and Rhinosinusitis. *Proc. Am. Thorac. Soc.* **2010**, *7*, 245–252. [[CrossRef](#)]
23. Bartemes, K.R.; Kita, H. Innate and Adaptive Immune Responses to Fungi in the Airway. *J. Allergy Clin. Immunol.* **2018**, *142*, 353–363. [[CrossRef](#)]
24. Marshall, J.S.; Warrington, R.; Watson, W.; Kim, H.L. An Introduction to Immunology and Immunopathology. *Allergy Asthma Clin. Immunol.* **2018**, *14*, 49. [[CrossRef](#)]
25. Vautier, S.; MacCallum, D.M.; Brown, G.D. C-Type Lectin Receptors and Cytokines in Fungal Immunity. *Cytokine* **2012**, *58*, 89–99. [[CrossRef](#)] [[PubMed](#)]
26. Wang, X.; Caffrey-Carr, A.K.; Liu, K.; Espinosa, V.; Croteau, W.; Dhingra, S.; Rivera, A.; Cramer, R.A.; Obar, J.J. MDA5 Is an Essential Sensor of a Pathogen-Associated Molecular Pattern Associated with Vitality That Is Necessary for Host Resistance against *Aspergillus Fumigatus*. *J. Immunol.* **2020**, *205*, 3058–3070. [[CrossRef](#)]
27. Espinosa, V.; Dutta, O.; McElrath, C.; Du, P.; Chang, Y.-J.; Ciccirelli, B.; Pitler, A.; Whitehead, I.; Obar, J.J.; Durbin, J.E.; et al. Type III Interferon Is a Critical Regulator of Innate Antifungal Immunity. *Sci. Immunol.* **2017**, *2*, eaan5357. [[CrossRef](#)] [[PubMed](#)]
28. Netea, M.G.; Brown, G.D.; Kullberg, B.J.; Gow, N.A.R. An Integrated Model of the Recognition of *Candida Albicans* by the Innate Immune System. *Nat. Rev. Microbiol.* **2008**, *6*, 67–78. [[CrossRef](#)] [[PubMed](#)]
29. Chai, L.Y.A.; Kullberg, B.J.; Vonk, A.G.; Warris, A.; Cambi, A.; Latgé, J.-P.; Joosten, L.A.B.; van der Meer, J.W.M.; Netea, M.G. Modulation of Toll-Like Receptor 2 (TLR2) and TLR4 Responses by *Aspergillus Fumigatus*. *Infect. Immun.* **2009**, *77*, 2184–2192. [[CrossRef](#)]
30. Patin, E.C.; Thompson, A.; Orr, S.J. Pattern Recognition Receptors in Fungal Immunity. *Semin. Cell Dev. Biol.* **2019**, *89*, 24–33. [[CrossRef](#)]
31. Jannuzzi, G.P.; de Almeida, J.R.F.; Paulo, L.N.M.; de Almeida, S.R.; Ferreira, K.S. Intracellular PRRs Activation in Targeting the Immune Response Against Fungal Infections. *Front. Cell. Infect. Microbiol.* **2020**, *10*, 562. [[CrossRef](#)]
32. Bourgeois, C.; Majer, O.; Frohner, I.E.; Lesiak-Markowicz, I.; Hildering, K.-S.; Glaser, W.; Stockinger, S.; Decker, T.; Akira, S.; Müller, M.; et al. Conventional Dendritic Cells Mount a Type I IFN Response against *Candida* Spp. Requiring Novel Phagosomal TLR7-Mediated IFN- β Signaling. *J. Immunol.* **2011**, *186*, 3104–3112. [[CrossRef](#)]
33. Ramirez-Ortiz, Z.G.; Specht, C.A.; Wang, J.P.; Lee, C.K.; Bartholomeu, D.C.; Gazzinelli, R.T.; Levitz, S.M. Toll-Like Receptor 9-Dependent Immune Activation by Unmethylated CpG Motifs in *Aspergillus Fumigatus* DNA. *Infect. Immun.* **2008**, *76*, 2123–2129. [[CrossRef](#)]
34. Kasperkovitz, P.V.; Khan, N.S.; Tam, J.M.; Mansour, M.K.; Davids, P.J.; Vyas, J.M. Toll-like Receptor 9 Modulates Macrophage Antifungal Effector Function during Innate Recognition of *Candida Albicans* and *Saccharomyces Cerevisiae*. *Infect. Immun.* **2011**, *79*, 4858–4867. [[CrossRef](#)]
35. Richardson, M.B.; Williams, S.J. MCL and MinCLE: C-Type Lectin Receptors That Sense Damaged Self and Pathogen-Associated Molecular Patterns. *Front. Immunol.* **2014**, *5*, 288. [[CrossRef](#)]
36. Fradin, C.; Poulain, D.; Jouault, T. β -1,2-Linked Oligomannosides from *Candida Albicans* Bind to a 32-Kilodalton Macrophage Membrane Protein Homologous to the Mammalian Lectin Galectin-3. *Infect. Immun.* **2000**, *68*, 4391–4398. [[CrossRef](#)]
37. Rajaram, M.V.S.; Arnett, E.; Azad, A.K.; Guirado, E.; Ni, B.; Gerberick, A.D.; He, L.-Z.; Keler, T.; Thomas, L.J.; Lafuse, W.P.; et al. M. Tuberculosis-Initiated Human Mannose Receptor Signaling Regulates Macrophage Recognition and Vesicle Trafficking by Fc γ -Chain, Grb2, and SHP-1. *Cell Rep.* **2017**, *21*, 126–140. [[CrossRef](#)]
38. Rosowski, E.E.; Raffa, N.; Knox, B.P.; Golenberg, N.; Keller, N.P.; Huttenlocher, A. Macrophages Inhibit *Aspergillus Fumigatus* Germination and Neutrophil-Mediated Fungal Killing. *PLoS Pathog.* **2018**, *14*, e1007229. [[CrossRef](#)]
39. Inglesfield, S.; Jasiulewicz, A.; Hopwood, M.; Tyrrell, J.; Youlden, G.; Mazon-Moya, M.; Millington, O.R.; Mostowy, S.; Jabbari, S.; Voelz, K. Robust Phagocyte Recruitment Controls the Opportunistic Fungal Pathogen *Mucor Circinelloides* in Innate Granulomas In Vivo. *mBio* **2018**, *9*, e02010-17. [[CrossRef](#)]
40. Uderhardt, S.; Martins, A.J.; Tsang, J.S.; Lämmermann, T.; Germain, R.N. Resident Macrophages Cloak Tissue Microlesions to Prevent Neutrophil-Driven Inflammatory Damage. *Cell* **2019**, *177*, 541–555.e17. [[CrossRef](#)]
41. Cagnina, R.E.; Michels, K.R.; Bettina, A.M.; Burdick, M.D.; Scindia, Y.; Zhang, Z.; Braciale, T.J.; Mehrad, B. Neutrophil-Derived Tumor Necrosis Factor Drives Fungal Acute Lung Injury in Chronic Granulomatous Disease. *J. Infect. Dis.* **2021**, *224*, 1225–1235. [[CrossRef](#)]

42. Gilbert, A.S.; Wheeler, R.T.; May, R.C. Fungal Pathogens: Survival and Replication within Macrophages. *Cold Spring Harb. Perspect. Med.* **2015**, *5*, a019661. [[CrossRef](#)]
43. Griffin, F.M.; Griffin, J.A.; Leider, J.E.; Silverstein, S.C. Studies on the Mechanism of Phagocytosis. I. Requirements for Circumferential Attachment of Particle-Bound Ligands to Specific Receptors on the Macrophage Plasma Membrane. *J. Exp. Med.* **1975**, *142*, 1263–1282. [[CrossRef](#)]
44. Rittig, M.G.; Schröppel, K.; Seack, K.-H.; Sander, U.; N'Diaye, E.-N.; Maridonneau-Parini, I.; Solbach, W.; Bogdan, C. Coiling Phagocytosis of Trypanosomatids and Fungal Cells. *Infect. Immun.* **1998**, *66*, 4331–4339. [[CrossRef](#)]
45. Bryan, A.M.; You, J.K.; Li, G.; Kim, J.; Singh, A.; Morstein, J.; Trauner, D.; Pereira de Sá, N.; Normile, T.G.; Farnoud, A.M.; et al. Cholesterol and Sphingomyelin Are Critical for Fcγ Receptor-Mediated Phagocytosis of *Cryptococcus Neoformans* by Macrophages. *J. Biol. Chem.* **2021**, *297*, 101411. [[CrossRef](#)]
46. Urso, K.; Charles, J.F.; Shull, G.E.; Aliprantis, A.O.; Balestrieri, B. Anion Exchanger 2 Regulates Dectin-1-Dependent Phagocytosis and Killing of *Candida Albicans*. *PLoS ONE* **2016**, *11*, e0158893. [[CrossRef](#)]
47. Schuit, K.E. Phagocytosis and Intracellular Killing of Pathogenic Yeasts by Human Monocytes and Neutrophils. *Infect. Immun.* **1979**, *24*, 932–938. [[CrossRef](#)]
48. Brown, G.D. Innate Antifungal Immunity: The Key Role of Phagocytes. *Annu. Rev. Immunol.* **2011**, *29*, 1–21. [[CrossRef](#)]
49. Hatinguais, R.; Pradhan, A.; Brown, G.D.; Brown, A.J.P.; Warris, A.; Shekhova, E. Mitochondrial Reactive Oxygen Species Regulate Immune Responses of Macrophages to *Aspergillus Fumigatus*. *Front. Immunol.* **2021**, *12*, 641495. [[CrossRef](#)]
50. Shlezinger, N.; Hohl, T.M. Mitochondrial Reactive Oxygen Species Enhance Alveolar Macrophage Activity against *Aspergillus Fumigatus* but Are Dispensable for Host Protection. *mSphere* **2021**, *6*, e00260-21. [[CrossRef](#)] [[PubMed](#)]
51. Dragotakes, Q.; Fu, M.S.; Casadevall, A. Dragocytosis: Elucidation of the Mechanism for *Cryptococcus Neoformans* Macrophage-to-Macrophage Transfer. *J. Immunol.* **2019**, *202*, 2661–2670. [[CrossRef](#)] [[PubMed](#)]
52. Shah, A.; Kannambath, S.; Herbst, S.; Rogers, A.; Soresi, S.; Carby, M.; Reed, A.; Mostowy, S.; Fisher, M.C.; Shaunak, S.; et al. Calcineurin Orchestrates Lateral Transfer of *Aspergillus Fumigatus* during Macrophage Cell Death. *Am. J. Respir. Crit. Care Med.* **2016**, *194*, 1127–1139. [[CrossRef](#)] [[PubMed](#)]
53. Ma, H.; Croudace, J.E.; Lammas, D.A.; May, R.C. Expulsion of Live Pathogenic Yeast by Macrophages. *Curr. Biol.* **2006**, *16*, 2156–2160. [[CrossRef](#)] [[PubMed](#)]
54. Bain, J.M.; Lewis, L.E.; Okai, B.; Quinn, J.; Gow, N.A.R.; Erwig, L.-P. Non-Lytic Expulsion/Exocytosis of *Candida Albicans* from Macrophages. *Fungal Genet. Biol.* **2012**, *49*, 677–678. [[CrossRef](#)]
55. Seoane, P.I.; Taylor-Smith, L.M.; Stirling, D.; Bell, L.C.K.; Noursadeghi, M.; Bailey, D.; May, R.C. Viral Infection Triggers Interferon-Induced Expulsion of Live *Cryptococcus Neoformans* by Macrophages. *PLoS Pathog.* **2020**, *16*, e1008240. [[CrossRef](#)]
56. Gilbert, A.S.; Seoane, P.I.; Sephton-Clark, P.; Bojarczuk, A.; Hotham, R.; Giurisato, E.; Sarhan, A.R.; Hillen, A.; Velde, G.V.; Gray, N.S.; et al. Vomocytosis of Live Pathogens from Macrophages Is Regulated by the Atypical MAP Kinase ERK5. *Sci. Adv.* **2017**, *3*, e1700898. [[CrossRef](#)]
57. Lewis, L.E.; Bain, J.M.; Lowes, C.; Gillespie, C.; Rudkin, F.M.; Gow, N.A.R.; Erwig, L.-P. Stage Specific Assessment of *Candida Albicans* Phagocytosis by Macrophages Identifies Cell Wall Composition and Morphogenesis as Key Determinants. *PLoS Pathog.* **2012**, *8*, e1002578. [[CrossRef](#)]
58. Okagaki, L.H.; Nielsen, K. Titan Cells Confer Protection from Phagocytosis in *Cryptococcus Neoformans* Infections. *Eukaryot. Cell* **2012**, *11*, 820–826. [[CrossRef](#)]
59. Knox, B.P.; Deng, Q.; Rood, M.; Eickhoff, J.C.; Keller, N.P.; Huttenlocher, A. Distinct Innate Immune Phagocyte Responses to *Aspergillus Fumigatus* Conidia and Hyphae in Zebrafish Larvae. *Eukaryot. Cell* **2014**, *13*, 1266–1277. [[CrossRef](#)]
60. Oghiso, Y.; Kubota, Y. Enhanced Interleukin 1 Production by Alveolar Macrophages and Increase in Ia-Positive Lung Cells in Silica-Exposed Rats. *Microbiol. Immunol.* **1986**, *30*, 1189–1198. [[CrossRef](#)]
61. Takemura, R.; Stenberg, P.E.; Bainton, D.F.; Werb, Z. Rapid Redistribution of Clathrin onto Macrophage Plasma Membranes in Response to Fc Receptor-Ligand Interaction during Frustrated Phagocytosis. *J. Cell Biol.* **1986**, *102*, 55–69. [[CrossRef](#)]
62. Uwamahoro, N.; Verma-Gaur, J.; Shen, H.-H.; Qu, Y.; Lewis, R.; Lu, J.; Bamberg, K.; Masters, S.L.; Vince, J.E.; Naderer, T.; et al. The Pathogen *Candida Albicans* Hijacks Pyroptosis for Escape from Macrophages. *Am. Soc. Microbiol.* **2014**, *5*, e00003-14. [[CrossRef](#)]
63. Bain, J.M.; Alonso, M.F.; Childers, D.S.; Walls, C.A.; Mackenzie, K.; Pradhan, A.; Lewis, L.E.; Louw, J.; Avelar, G.M.; Larcombe, D.E.; et al. Immune Cells Fold and Damage Fungal Hyphae. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2020484118. [[CrossRef](#)]
64. Atri, C.; Guerfali, F.Z.; Laouini, D. Role of Human Macrophage Polarization in Inflammation during Infectious Diseases. *Int. J. Mol. Sci.* **2018**, *19*, 1801. [[CrossRef](#)]
65. Subramani, A.; Griggs, P.; Frantzen, N.; Mendez, J.; Tucker, J.; Murriel, J.; Sircy, L.M.; Millican, G.E.; McClelland, E.E.; Seipelt-Thiemann, R.L.; et al. Intracellular *Cryptococcus Neoformans* Disrupts the Transcriptome Profile of M1- and M2-Polarized Host Macrophages. *PLoS ONE* **2020**, *15*, e0233818. [[CrossRef](#)]
66. Reales-Calderón, J.A.; Aguilera-Montilla, N.; Corbí, Á.L.; Molero, G.; Gil, C. Proteomic Characterization of Human Proinflammatory M1 and Anti-Inflammatory M2 Macrophages and Their Response to *Candida Albicans*. *Proteomics* **2014**, *14*, 1503–1518. [[CrossRef](#)]
67. Hardison, S.E.; Herrera, G.; Young, M.L.; Hole, C.R.; Wozniak, K.L.; Wormley, F.L. Protective Immunity against Pulmonary Cryptococcosis Is Associated with STAT1-Mediated Classical Macrophage Activation. *J. Immunol.* **2012**, *189*, 4060–4068. [[CrossRef](#)]

68. Gao, Q.; Zhang, J.; Chen, C.; Chen, M.; Sun, P.; Du, W.; Zhang, S.; Liu, Y.; Zhang, R.; Bai, M.; et al. In Situ Mannosylated Nanotrinity-Mediated Macrophage Remodeling Combats *Candida Albicans* Infection. *ACS Nano* **2020**, *14*, 3980–3990. [[CrossRef](#)]
69. Luvanda, M.K.; Posch, W.; Vosper, J.; Zaderer, V.; Noureen, A.; Lass-Flörl, C.; Wilflingseder, D. Dexamethasone Promotes *Aspergillus Fumigatus* Growth in Macrophages by Triggering M2 Repolarization via Targeting PKM2. *J. Fungi* **2021**, *7*, 70. [[CrossRef](#)]
70. Drummond, R.A.; Muthulekha, S.; Vasileios, O.; Bing, Z.; Dambuza, I.M.; Schaefer, B.C.; Bohrer, A.C.; Mayer-Barber, K.D.; Lira, S.A.; Yoichiro, I.; et al. CARD9+ Microglia Promote Antifungal Immunity via IL-1 β - and CXCL1-Mediated Neutrophil Recruitment. *Nat. Immunol.* **2019**, *20*, 559–570. [[CrossRef](#)]
71. Nguyen, N.Z.N.; Tran, V.G.; Baek, J.; Kim, Y.; Youn, E.H.; Na, S.W.; Park, S.J.; Seo, S.-K.; Kwon, B. IL-33 Coordinates Innate Defense to Systemic *Candida Albicans* Infection by Regulating IL-23 and IL-10 in an Opposite Way. *J. Immunol.* **2022**, *208*, 660–671. [[CrossRef](#)]
72. Lilly, L.M.; Scopel, M.; Nelson, M.P.; Burg, A.R.; Dunaway, C.W.; Steele, C. Eosinophil Deficiency Compromises Lung Defense against *Aspergillus Fumigatus*. *Infect. Immun.* **2014**, *82*, 1315–1325. [[CrossRef](#)]
73. Yadav, B.; Specht, C.A.; Lee, C.K.; Pokrovskii, M.; Huh, J.R.; Littman, D.R.; Levitz, S.M. Lung Eosinophils Elicited during Allergic and Acute Aspergillosis Express ROR γ t and IL-23R but Do Not Require IL-23 for IL-17 Production. *PLoS Pathog.* **2021**, *17*, e1009891. [[CrossRef](#)]
74. de Oliveira Malacco, N.L.S.; Rachid, M.A.; da Silva Gurgel, I.L.; Moura, T.R.; Sucupira, P.H.F.; de Sousa, L.P.; da Glória de Souza, D.; de Castro Russo, R.; Teixeira, M.M.; Soriani, F.M. Eosinophil-Associated Innate IL-17 Response Promotes *Aspergillus Fumigatus* Lung Pathology. *Front. Cell. Infect. Microbiol.* **2019**, *8*, 453. [[CrossRef](#)]
75. Yamasaki, S.; Matsumoto, M.; Takeuchi, O.; Matsuzawa, T.; Ishikawa, E.; Sakuma, M.; Tateno, H.; Uno, J.; Hirabayashi, J.; Mikami, Y.; et al. C-Type Lectin Mincle Is an Activating Receptor for Pathogenic Fungus, *Malassezia*. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 1897–1902. [[CrossRef](#)]
76. Swidergall, M.; Khalaji, M.; Solis, N.V.; Moyes, D.L.; Drummond, R.A.; Hube, B.; Lionakis, M.S.; Murdoch, C.; Filler, S.G.; Naglik, J.R. Candidalysin Is Required for Neutrophil Recruitment and Virulence During Systemic *Candida Albicans* Infection. *J. Infect. Dis.* **2019**, *220*, 1477–1488. [[CrossRef](#)] [[PubMed](#)]
77. Richardson, J.P.; Willems, H.M.E.; Moyes, D.L.; Shoaie, S.; Barker, K.S.; Tan, S.L.; Palmer, G.E.; Hube, B.; Naglik, J.R.; Peters, B.M. Candidalysin Drives Epithelial Signaling, Neutrophil Recruitment, and Immunopathology at the Vaginal Mucosa. *Infect. Immun.* **2018**, *86*, e00645-17. [[CrossRef](#)] [[PubMed](#)]
78. Bai, W.; Wang, Q.; Deng, Z.; Li, T.; Xiao, H.; Wu, Z. TRAF1 Suppresses Antifungal Immunity through CXCL1-Mediated Neutrophil Recruitment during *Candida Albicans* Intradermal Infection. *Cell Commun. Signal.* **2020**, *18*, 30. [[CrossRef](#)] [[PubMed](#)]
79. Carpentier, I.; Beyaert, R. TRAF1 Is a TNF Inducible Regulator of NF-KB Activation. *FEBS Lett.* **1999**, *460*, 246–250. [[CrossRef](#)]
80. Ho, J.; Yang, X.; Nikou, S.-A.; Kichik, N.; Donkin, A.; Ponde, N.O.; Richardson, J.P.; Gratacap, R.L.; Archambault, L.S.; Zwirner, C.P.; et al. Candidalysin Activates Innate Epithelial Immune Responses via Epidermal Growth Factor Receptor. *Nat. Commun.* **2019**, *10*, 2297. [[CrossRef](#)]
81. Swidergall, M.; Solis, N.V.; Millet, N.; Huang, M.Y.; Lin, J.; Phan, Q.T.; Lazarus, M.D.; Wang, Z.; Yeaman, M.R.; Mitchell, A.P.; et al. Activation of EphA2-EGFR Signaling in Oral Epithelial Cells by *Candida Albicans* Virulence Factors. *PLoS Pathog.* **2021**, *17*, e1009221. [[CrossRef](#)]
82. Le, H.T.; Tran, V.G.; Kim, W.; Kim, J.; Cho, H.R.; Kwon, B. IL-33 Priming Regulates Multiple Steps of the Neutrophil-Mediated Anti-*Candida Albicans* Response by Modulating TLR and Dectin-1 Signals. *J. Immunol.* **2012**, *189*, 287–295. [[CrossRef](#)]
83. Alvarez-Rueda, N.; Rouges, C.; Touahri, A.; Misme-Aucouturier, B.; Albassier, M.; Pape, P.L. In Vitro Immune Responses of Human PBMCs against *Candida Albicans* Reveals Fungal and Leucocyte Phenotypes Associated with Fungal Persistence. *Sci. Rep.* **2020**, *10*, 6211. [[CrossRef](#)]
84. Nur, S.; Sparber, F.; Lemberg, C.; Guiducci, E.; Schweizer, T.A.; Zwicky, P.; Becher, B.; LeibundGut-Landmann, S. IL-23 Supports Host Defense against Systemic *Candida Albicans* Infection by Ensuring Myeloid Cell Survival. *PLoS Pathog.* **2019**, *15*, e1008115. [[CrossRef](#)]
85. Lämmermann, T.; Afonso, P.V.; Angermann, B.R.; Wang, J.M.; Kastenmüller, W.; Parent, C.A.; Germain, R.N. Neutrophil Swarms Require LTB4 and Integrins at Sites of Cell Death in Vivo. *Nature* **2013**, *498*, 371–375. [[CrossRef](#)]
86. Sun, D.; Shi, M. Neutrophil Swarming toward *Cryptococcus Neoformans* Is Mediated by Complement and Leukotriene B4. *Biochem. Biophys. Res. Commun.* **2016**, *477*, 945–951. [[CrossRef](#)]
87. Hopke, A.; Scherer, A.; Kreuzburg, S.; Abers, M.S.; Zerbe, C.S.; Dinauer, M.C.; Mansour, M.K.; Irimia, D. Neutrophil Swarming Delays the Growth of Clusters of Pathogenic Fungi. *Nat. Commun.* **2020**, *11*, 2031. [[CrossRef](#)]
88. Hind, L.E.; Giese, M.A.; Schoen, T.J.; Beebe, D.J.; Keller, N.; Huttenlocher, A. Immune Cell Paracrine Signaling Drives the Neutrophil Response to *A. Fumigatus* in an Infection-on-a-Chip Model. *Cell. Mol. Bioeng.* **2021**, *14*, 133–145. [[CrossRef](#)]
89. Lämmermann, T. In the Eye of the Neutrophil Swarm—Navigation Signals That Bring Neutrophils Together in Inflamed and Infected Tissues. *J. Leukoc. Biol.* **2016**, *100*, 55–63. [[CrossRef](#)]
90. Lee, E.K.S.; Gillrie, M.R.; Li, L.; Arnason, J.W.; Kim, J.H.; Babes, L.; Lou, Y.; Sanati-Nezhad, A.; Kyei, S.K.; Kelly, M.M.; et al. Leukotriene B4-Mediated Neutrophil Recruitment Causes Pulmonary Capillaritis during Lethal Fungal Sepsis. *Cell Host Microbe* **2018**, *23*, 121–133.e4. [[CrossRef](#)]
91. Lacy, P. Mechanisms of Degranulation in Neutrophils. *Allergy Asthma Clin. Immunol.* **2006**, *2*, 98–108. [[CrossRef](#)] [[PubMed](#)]

92. Diamond, R.D.; Krzesicki, R.; Jao, W. Damage to Pseudohyphal Forms of *Candida Albicans* by Neutrophils in the Absence of Serum In Vitro. *J. Clin. Investig.* **1978**, *61*, 349–359. [[CrossRef](#)] [[PubMed](#)]
93. Hartl, D.; Latzin, P.; Hordijk, P.; Marcos, V.; Rudolph, C.; Woischnik, M.; Krauss-Etschmann, S.; Koller, B.; Reinhardt, D.; Roscher, A.A.; et al. Cleavage of CXCR1 on Neutrophils Disables Bacterial Killing in Cystic Fibrosis Lung Disease. *Nat. Med.* **2007**, *13*, 1423–1430. [[CrossRef](#)] [[PubMed](#)]
94. Swamydas, M.; Gao, J.-L.; Break, T.J.; Johnson, M.D.; Jaeger, M.; Rodriguez, C.A.; Lim, J.K.; Green, N.M.; Collar, A.L.; Fischer, B.G.; et al. CXCR1-Mediated Neutrophil Degranulation and Fungal Killing Promotes *Candida* Clearance and Host Survival. *Sci. Transl. Med.* **2016**, *8*, 322ra10. [[CrossRef](#)] [[PubMed](#)]
95. Winterbourn, C.C.; Hampton, M.B.; Livesey, J.H.; Kettle, A.J. Modeling the Reactions of Superoxide and Myeloperoxidase in the Neutrophil Phagosome: Implications for Microbial Killing. *J. Biol. Chem.* **2006**, *281*, 39860–39869. [[CrossRef](#)]
96. Dupré-Crochet, S.; Erard, M.; Nüße, O. ROS Production in Phagocytes: Why, When, and Where? *J. Leukoc. Biol.* **2013**, *94*, 657–670. [[CrossRef](#)]
97. Urban, C.F.; Ermert, D.; Schmid, M.; Abu-Abed, U.; Goosmann, C.; Nacken, W.; Brinkmann, V.; Jungblut, P.R.; Zychlinsky, A. Neutrophil Extracellular Traps Contain Calprotectin, a Cytosolic Protein Complex Involved in Host Defense against *Candida Albicans*. *PLoS Pathog.* **2009**, *5*, e1000639. [[CrossRef](#)]
98. Urban, C.F.; Reichard, U.; Brinkmann, V.; Zychlinsky, A. Neutrophil Extracellular Traps Capture and Kill *Candida Albicans* Yeast and Hyphal Forms. *Cell. Microbiol.* **2006**, *8*, 668–676. [[CrossRef](#)]
99. Bianchi, M.; Hakkim, A.; Brinkmann, V.; Siler, U.; Seger, R.A.; Zychlinsky, A.; Reichenbach, J. Restoration of NET Formation by Gene Therapy in CGD Controls Aspergillosis. *Blood* **2009**, *114*, 2619–2622. [[CrossRef](#)]
100. Isles, H.M.; Loynes, C.A.; Alasmari, S.; Kon, F.C.; Henry, K.M.; Kadochnikova, A.; Hales, J.; Muir, C.F.; Keightley, M.-C.; Kadirkamanathan, V.; et al. Pioneer Neutrophils Release Chromatin within in Vivo Swarms. *eLife* **2021**, *10*, e68755. [[CrossRef](#)]
101. Wilson, A.S.; Randall, K.L.; Pettitt, J.A.; Ellyard, J.I.; Blumenthal, A.; Enders, A.; Quah, B.J.; Bopp, T.; Parish, C.R.; Brüstle, A. Neutrophil Extracellular Traps and Their Histones Promote Th17 Cell Differentiation Directly via TLR2. *Nat. Commun.* **2022**, *13*, 528. [[CrossRef](#)]
102. Mengesha, B.G.; Conti, H.R. The Role of IL-17 in Protection against Mucosal *Candida* Infections. *J. Fungi* **2017**, *3*, 52. [[CrossRef](#)]
103. Taylor, P.R.; Leal, S.M.; Sun, Y.; Pearlman, E. *Aspergillus* and *Fusarium* Corneal Infections Are Regulated by Th17 Cells and IL-17–Producing Neutrophils. *J. Immunol.* **2014**, *192*, 3319–3327. [[CrossRef](#)]
104. Rohrbach, A.; Slade, D.; Thompson, P.; Mowen, K. Activation of PAD4 in NET Formation. *Front. Immunol.* **2012**, *3*, 360. [[CrossRef](#)]
105. Guiducci, E.; Lemberg, C.; Küng, N.; Schraner, E.; Theocharides, A.P.A.; LeibundGut-Landmann, S. *Candida Albicans*-Induced NETosis Is Independent of Peptidylarginine Deiminase 4. *Front. Immunol.* **2018**, *9*, 1573. [[CrossRef](#)]
106. Tatsiy, O.; McDonald, P.P. Physiological Stimuli Induce PAD4-Dependent, ROS-Independent NETosis, With Early and Late Events Controlled by Discrete Signaling Pathways. *Front. Immunol.* **2018**, *9*, 2036. [[CrossRef](#)]
107. Thiam, H.R.; Wong, S.L.; Qiu, R.; Kittisopikul, M.; Vahabikashi, A.; Goldman, A.E.; Goldman, R.D.; Wagner, D.D.; Waterman, C.M. NETosis Proceeds by Cytoskeleton and Endomembrane Disassembly and PAD4-Mediated Chromatin Decondensation and Nuclear Envelope Rupture. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 7326–7337. [[CrossRef](#)]
108. Clark, H.L.; Abbondante, S.; Minns, M.S.; Greenberg, E.N.; Sun, Y.; Pearlman, E. Protein Deiminase 4 and CR3 Regulate *Aspergillus Fumigatus* and β -Glucan-Induced Neutrophil Extracellular Trap Formation, but Hyphal Killing Is Dependent Only on CR3. *Front. Immunol.* **2018**, *9*, 1182. [[CrossRef](#)]
109. Silva, J.C.; Rodrigues, N.C.; Thompson-Souza, G.A.; de Muniz, V.S.; Neves, J.S.; Figueiredo, R.T. Mac-1 Triggers Neutrophil DNA Extracellular Trap Formation to *Aspergillus Fumigatus* Independently of PAD4 Histone Citrullination. *J. Leukoc. Biol.* **2020**, *107*, 69–83. [[CrossRef](#)]
110. Karkowska-Kuleta, J.; Smolarz, M.; Seweryn-Ozog, K.; Satala, D.; Zawrotniak, M.; Wronowska, E.; Bochenska, O.; Kozik, A.; Nobbs, A.H.; Gogol, M.; et al. Proteinous Components of Neutrophil Extracellular Traps Are Arrested by the Cell Wall Proteins of *Candida Albicans* during Fungal Infection, and Can Be Used in the Host Invasion. *Cells* **2021**, *10*, 2736. [[CrossRef](#)]
111. Alflen, A.; Lopez, P.A.; Hartmann, A.-K.; Maxeiner, J.; Bosmann, M.; Sharma, A.; Platten, J.; Ries, F.; Beckert, H.; Ruf, W.; et al. Neutrophil Extracellular Traps Impair Fungal Clearance in a Mouse Model of Invasive Pulmonary Aspergillosis. *Immunobiology* **2020**, *225*, 151867. [[CrossRef](#)] [[PubMed](#)]
112. Pazhakh, V.; Ellett, F.; Croker, B.A.; O'Donnell, J.A.; Pase, L.; Schulze, K.E.; Greulich, R.S.; Gupta, A.; Reyes-Aldasoro, C.C.; Andrianopoulos, A.; et al. β -Glucan-Dependent Shuttling of Conidia from Neutrophils to Macrophages Occurs during Fungal Infection Establishment. *PLoS Biol.* **2019**, *17*, e3000113. [[CrossRef](#)] [[PubMed](#)]
113. Inoue, Y.; Matsuwaki, Y.; Shin, S.-H.; Ponikau, J.U.; Kita, H. Nonpathogenic, Environmental Fungi Induce Activation and Degranulation of Human Eosinophils. *J. Immunol.* **2005**, *175*, 5439–5447. [[CrossRef](#)] [[PubMed](#)]
114. Gladiator, A.; Wangler, N.; Trautwein-Weidner, K.; LeibundGut-Landmann, S. Cutting Edge: IL-17–Secreting Innate Lymphoid Cells Are Essential for Host Defense against Fungal Infection. *J. Immunol.* **2013**, *190*, 521–525. [[CrossRef](#)] [[PubMed](#)]
115. Reeder, K.M.; Mackel, J.J.; Godwin, M.S.; Dunaway, C.W.; Blackburn, J.P.; Patel, R.P.; Steele, C. Role of Common γ -Chain Cytokines in Lung Interleukin-22 Regulation after Acute Exposure to *Aspergillus Fumigatus*. *Infect. Immun.* **2018**, *86*, e00157-18. [[CrossRef](#)]
116. Di Luccia, B.; Gilfillan, S.; Cella, M.; Colanna, M.; Huang, S.C.-C. ILC3s Integrate Glycolysis and Mitochondrial Production of Reactive Oxygen Species to Fulfill Activation Demands | Journal of Experimental Medicine | Rockefeller University Press. *J. Exp. Med.* **2019**, *216*, 2231–2241. [[CrossRef](#)]

117. Böttger, E.C.; Metzger, S.; Bitter-Suermann, D.; Stevenson, G.; Kleindienst, S.; Burger, R. Impaired Humoral Immune Response in Complement C3-Deficient Guinea Pigs: Absence of Secondary Antibody Response. *Eur. J. Immunol.* **1986**, *16*, 1231–1235. [[CrossRef](#)]
118. Tsoni, S.V.; Kerrigan, A.M.; Marakalala, M.J.; Srinivasan, N.; Duffield, M.; Taylor, P.R.; Botto, M.; Steele, C.; Brown, G.D. Complement C3 Plays an Essential Role in the Control of Opportunistic Fungal Infections. *Infect. Immun.* **2009**, *77*, 3679–3685. [[CrossRef](#)]
119. Teschner, D.; Cholaszczyńska, A.; Ries, F.; Beckert, H.; Theobald, M.; Grabbe, S.; Radsak, M.; Bros, M. CD11b Regulates Fungal Outgrowth but Not Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis. *Front. Immunol.* **2019**, *10*, 123. [[CrossRef](#)]
120. O'Brien, X.M.; Heflin, K.E.; Lavigne, L.M.; Yu, K.; Kim, M.; Salomon, A.R.; Reichner, J.S. Lectin Site Ligation of CR3 Induces Conformational Changes and Signaling*. *J. Biol. Chem.* **2012**, *287*, 3337–3348. [[CrossRef](#)]
121. van Bruggen, R.; Drewniak, A.; Jansen, M.; van Houdt, M.; Roos, D.; Chapel, H.; Verhoeven, A.J.; Kuijpers, T.W. Complement Receptor 3, Not Dectin-1, Is the Major Receptor on Human Neutrophils for β -Glucan-Bearing Particles. *Mol. Immunol.* **2009**, *47*, 575–581. [[CrossRef](#)]
122. Johnson, C.M.; O'Brien, X.M.; Byrd, A.S.; Parisi, V.E.; Loosely, A.J.; Li, W.; Witt, H.; Faridi, H.M.; Lefort, C.T.; Gupta, V.; et al. Integrin Cross-Talk Regulates the Human Neutrophil Response to Fungal β -Glucan in the Context of the Extracellular Matrix: A Prominent Role for VLA3 in the Antifungal Response. *J. Immunol.* **2017**, *198*, 318–334. [[CrossRef](#)]
123. Liu, Y.; Li, Z.; Wang, S.; Zhang, C.; Han, L.; Sun, Q.; Han, X. Aspergillus Fumigatus Induces the Release of IL-8 and MCP-1 by Activating Nuclear Transcription Through Dectin-1 and CR3 Receptors in Alveolar Epithelial Cells. *Curr. Microbiol.* **2021**, *78*, 3474–3482. [[CrossRef](#)]
124. Nobile, C.J.; Johnson, A.D. Candida Albicans Biofilms and Human Disease. *Annu. Rev. Microbiol.* **2015**, *69*, 71–92. [[CrossRef](#)]
125. Carolus, H.; Van Dyck, K.; Van Dijck, P. Candida Albicans and Staphylococcus Species: A Threatening Twosome. *Front. Microbiol.* **2019**, *10*, 2162. [[CrossRef](#)]
126. Yapar, N. Epidemiology and Risk Factors for Invasive Candidiasis. *Ther. Clin. Risk Manag.* **2014**, *10*, 95–105. [[CrossRef](#)]
127. Okada, S.; Puel, A.; Casanova, J.-L.; Kobayashi, M. Chronic Mucocutaneous Candidiasis Disease Associated with Inborn Errors of IL-17 Immunity. *Clin. Transl. Immunol.* **2016**, *5*, e114. [[CrossRef](#)]
128. Humbert, L.; Cornu, M.; Proust-Lemoine, E.; Bayry, J.; Wemeau, J.-L.; Vantyghem, M.-C.; Sendid, B. Chronic Mucocutaneous Candidiasis in Autoimmune Polyendocrine Syndrome Type 1. *Front. Immunol.* **2018**, *9*, 2570. [[CrossRef](#)]
129. Bassetti, M.; Giacobbe, D.R.; Vena, A.; Trucchi, C.; Ansaldo, F.; Antonelli, M.; Adamkova, V.; Alicino, C.; Almyroudi, M.-P.; Atchade, E.; et al. Incidence and Outcome of Invasive Candidiasis in Intensive Care Units (ICUs) in Europe: Results of the EUCANDICU Project. *Crit. Care* **2019**, *23*, 219. [[CrossRef](#)]
130. Maródi, L.; Cypowyj, S.; Tóth, B.; Chernyshova, L.; Puel, A.; Casanova, J.-L. Molecular Mechanisms of Mucocutaneous Immunity against Candida and Staphylococcus Species. *J. Allergy Clin. Immunol.* **2012**, *130*, 1019–1027. [[CrossRef](#)]
131. Lanternier, F.; Cypowyj, S.; Picard, C.; Bustamante, J.; Lortholary, O.; Casanova, J.-L.; Puel, A. Primary Immunodeficiencies Underlying Fungal Infections. *Curr. Opin. Pediatrics* **2013**, *25*, 736–747. [[CrossRef](#)]
132. Corvilain, E.; Casanova, J.-L.; Puel, A. Inherited CARD9 Deficiency: Invasive Disease Caused by Ascomycete Fungi in Previously Healthy Children and Adults. *J. Clin. Immunol.* **2018**, *38*, 656–693. [[CrossRef](#)]
133. Drummond, R.A.; Saijo, S.; Iwakura, Y.; Brown, G.D. The Role of Syk/CARD9 Coupled C-Type Lectins in Antifungal Immunity. *Eur. J. Immunol.* **2011**, *41*, 276–281. [[CrossRef](#)]
134. Drummond, R.A.; Collar, A.L.; Swamydas, M.; Rodriguez, C.A.; Lim, J.K.; Mendez, L.M.; Fink, D.L.; Hsu, A.P.; Zhai, B.; Karauzum, H.; et al. CARD9-Dependent Neutrophil Recruitment Protects against Fungal Invasion of the Central Nervous System. *PLoS Pathog.* **2015**, *11*, e1005293. [[CrossRef](#)] [[PubMed](#)]
135. Chen, X.; Zhang, H.; Wang, X.; Shao, Z.; Li, Y.; Zhao, G.; Liu, F.; Liu, B.; Zheng, Y.; Chen, T.; et al. OTUD1 Regulates Antifungal Innate Immunity through Deubiquitination of CARD9. *J. Immunol.* **2021**, *206*, 1832–1843. [[CrossRef](#)] [[PubMed](#)]
136. Picard, C.; Casanova, J.-L.; Puel, A. Infectious Diseases in Patients with IRAK-4, MyD88, NEMO, or I κ B α Deficiency. *Clin. Microbiol. Rev.* **2011**, *24*, 490–497. [[CrossRef](#)] [[PubMed](#)]
137. Villamón, E.; Gozalbo, D.; Roig, P.; Murciano, C.; O'Connor, J.E.; Fradelizi, D.; Gil, M.L. Myeloid Differentiation Factor 88 (MyD88) Is Required for Murine Resistance to Candida Albicans and Is Critically Involved in Candida-Induced Production of Cytokines. *Eur. Cytokine Netw.* **2004**, *15*, 263–271. [[PubMed](#)]
138. Hu, W.; van Steijn, L.; Li, C.; Verbeek, F.J.; Cao, L.; Merks, R.M.H.; Spaink, H.P. A Novel Function of TLR2 and MyD88 in the Regulation of Leukocyte Cell Migration Behavior during Wounding in Zebrafish Larvae. *Front. Cell Dev. Biol.* **2021**, *9*, 210. [[CrossRef](#)]
139. Huppler, A.R.; Conti, H.R.; Hernández-Santos, N.; Darville, T.; Biswas, P.S.; Gaffen, S.L. Role of Neutrophils in IL-17-Dependent Immunity to Mucosal Candidiasis. *J. Immunol.* **2014**, *192*, 1745–1752. [[CrossRef](#)]
140. Kao, C.-Y.; Chen, Y.; Thai, P.; Wachi, S.; Huang, F.; Kim, C.; Harper, R.W.; Wu, R. IL-17 Markedly up-Regulates Beta-Defensin-2 Expression in Human Airway Epithelium via JAK and NF-KappaB Signaling Pathways. *J. Immunol.* **2004**, *173*, 3482–3491. [[CrossRef](#)]

141. Davidson, L.; van den Reek, J.M.P.A.; Bruno, M.; van Hunsel, F.; Herings, R.M.C.; Matzaraki, V.; Boahen, C.K.; Kumar, V.; Groenewoud, H.M.M.; van de Veerdonk, F.L.; et al. Risk of Candidiasis Associated with Interleukin-17 Inhibitors: A Real-World Observational Study of Multiple Independent Sources. *Lancet Reg. Health Eur.* **2022**, *13*, 10266. [[CrossRef](#)]
142. Chimenz, R.; Tropeano, A.; Chirico, V.; Ceravolo, G.; Salpietro, C.; Cuppari, C. IL-17 Serum Level in Patients with Chronic Mucocutaneous Candidiasis Disease. *Pediatric Allergy Immunol.* **2022**, *33*, 77–79. [[CrossRef](#)]
143. Puel, A.; Cypowyj, S.; Maródi, L.; Abel, L.; Picard, C.; Casanova, J.-L. Inborn Errors of Human IL-17 Immunity Underlie Chronic Mucocutaneous Candidiasis. *Curr. Opin. Allergy Clin. Immunol.* **2012**, *12*, 616–622. [[CrossRef](#)]
144. Puel, A.; Döffinger, R.; Natividad, A.; Chrabieh, M.; Barcenas-Morales, G.; Picard, C.; Cobat, A.; Ouachée-Chardin, M.; Toulon, A.; Bustamante, J.; et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in Patients with Chronic Mucocutaneous Candidiasis and Autoimmune Polyendocrine Syndrome Type I. *J. Exp. Med.* **2010**, *207*, 291–297. [[CrossRef](#)]
145. Kisand, K.; Bøe Wolff, A.S.; Podkrajšek, K.T.; Tserel, L.; Link, M.; Kisand, K.V.; Ersvaer, E.; Perheentupa, J.; Erichsen, M.M.; Bratanic, N.; et al. Chronic Mucocutaneous Candidiasis in APECED or Thymoma Patients Correlates with Autoimmunity to Th17-Associated Cytokines. *J. Exp. Med.* **2010**, *207*, 299–308. [[CrossRef](#)]
146. Bader, O.; Weig, M.S.; Gross, U.; Schön, M.P.; Mempel, M.; Buhl, T. Photo Quiz. A 32-Year-Old Man with Ulcerative Mucositis, Skin Lesions, and Nail Dystrophy. Chronic Mucocutaneous Candidiasis by Multidrug-Resistant *Candida Albicans*. *Clin. Infect. Dis.* **2012**, *54*, 972, 1035–1036. [[CrossRef](#)]
147. Tanaka, N.; Watanabe, J.; Kitamura, T.; Yamada, Y.; Kanegasaki, S.; Nakata, K. Lungs of Patients with Idiopathic Pulmonary Alveolar Proteinosis Express a Factor Which Neutralizes Granulocyte-Macrophage Colony Stimulating Factor. *FEBS Lett.* **1999**, *442*, 246–250. [[CrossRef](#)]
148. Chen, G.-H.; Teitz-Tennenbaum, S.; Neal, L.M.; Murdock, B.J.; Malachowski, A.N.; Dils, A.J.; Olszewski, M.A.; Osterholzer, J.J. Local GM-CSF-Dependent Differentiation and Activation of Pulmonary Dendritic Cells and Macrophages Protect against Progressive Cryptococcal Lung Infection in Mice. *J. Immunol.* **2016**, *196*, 1810–1821. [[CrossRef](#)]
149. Rajasingham, R.; Smith, R.M.; Park, B.J.; Jarvis, J.N.; Govender, N.P.; Chiller, T.M.; Denning, D.W.; Loyse, A.; Boulware, D.R. Global Burden of Disease of HIV-Associated Cryptococcal Meningitis: An Updated Analysis. *Lancet Infect. Dis.* **2017**, *17*, 873–881. [[CrossRef](#)]
150. de Araújo, G.R.S.; de Alcantara, C.L.; Rodrigues, N.; de Souza, W.; Pontes, B.; Frases, S. Ultrastructural Study of *Cryptococcus Neoformans* Surface During Budding Events. *Front. Microbiol.* **2021**, *12*, 405. [[CrossRef](#)]
151. Esher, S.K.; Zaragoza, O.; Alspaugh, J.A. Cryptococcal Pathogenic Mechanisms: A Dangerous Trip from the Environment to the Brain. *Mem. Inst. Oswaldo Cruz* **2018**, *113*, e180057. [[CrossRef](#)]
152. Chayakulkeeree, M.; Perfect, J.R. Cryptococcosis. *Infect. Dis. Clin. N. Am.* **2006**, *20*, 507–544. [[CrossRef](#)]
153. Bartlett, K.H.; Kidd, S.E.; Kronstad, J.W. The Emergence of *Cryptococcus Gattii* in British Columbia and the Pacific Northwest. *Curr. Infect. Dis. Rep.* **2008**, *10*, 58–65. [[CrossRef](#)]
154. May, R.C.; Stone, N.R.H.; Wiesner, D.L.; Bicanic, T.; Nielsen, K. *Cryptococcus*: From Environmental Saprophyte to Global Pathogen. *Nat. Rev. Microbiol.* **2016**, *14*, 106–117. [[CrossRef](#)]
155. Rosen, L.B.; Freeman, A.F.; Yang, L.M.; Jutivorakool, K.; Olivier, K.N.; Angkasekwinai, N.; Suputtamongkol, Y.; Bennett, J.E.; Pyrgos, V.; Williamson, P.R.; et al. Anti-GM-CSF Autoantibodies in Patients with Cryptococcal Meningitis. *J. Immunol.* **2013**, *190*, 3959–3966. [[CrossRef](#)]
156. Saijo, T.; Chen, J.; Chen, S.C.-A.; Rosen, L.B.; Yi, J.; Sorrell, T.C.; Bennett, J.E.; Holland, S.M.; Browne, S.K.; Kwon-Chung, K.J. Anti-Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies Are a Risk Factor for Central Nervous System Infection by *Cryptococcus Gattii* in Otherwise Immunocompetent Patients. *mBio* **2014**, *5*, e00912-14. [[CrossRef](#)]
157. Perrineau, S.; Guery, R.; Monnier, D.; Puel, A.; Lanternier, F. Anti-GM-CSF Autoantibodies and *Cryptococcus Neoformans* Var. *Grubii* CNS Vasculitis. *J. Clin. Immunol.* **2020**, *40*, 767–769. [[CrossRef](#)] [[PubMed](#)]
158. Kitamura, T.; Tanaka, N.; Watanabe, J.; Uchida, Kanegasaki, S.; Yamada, Y.; Nakata, K. Idiopathic Pulmonary Alveolar Proteinosis as an Autoimmune Disease with Neutralizing Antibody against Granulocyte/Macrophage Colony-Stimulating Factor. *J. Exp. Med.* **1999**, *190*, 875–880. [[CrossRef](#)] [[PubMed](#)]
159. Bandres, M.V.; Modi, P.; Sharma, S. *Aspergillus fumigatus*. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2021.
160. Kolwijck, E.; van de Veerdonk, F.L. The Potential Impact of the Pulmonary Microbiome on Immunopathogenesis of *Aspergillus*-Related Lung Disease. *Eur. J. Immunol.* **2014**, *44*, 3156–3165. [[CrossRef](#)] [[PubMed](#)]
161. Roth, R.S.; Masouridi-Levrat, S.; Chalandon, Y.; Mamez, A.-C.; Giannotti, F.; Riat, A.; Fischer, A.; Poncet, A.; Glampedakis, E.; Van Delden, C.; et al. Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress? *Open Forum Infect. Dis.* **2021**, *9*, ofab596. [[CrossRef](#)] [[PubMed](#)]
162. Ferdjallah, A.; Young, J.-A.H.; MacMillan, M.L. A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key. *Front. Pediatrics* **2021**, *9*, 634449. [[CrossRef](#)]
163. Luo, X.-L.; Li, J.-X.; Huang, H.-R.; Duan, J.-L.; Dai, R.-X.; Tao, R.-J.; Yang, L.; Hou, J.; Jia, X.-M.; Xu, J.-F. LL37 Inhibits *Aspergillus Fumigatus* Infection via Directly Binding to the Fungus and Preventing Excessive Inflammation. *Front. Immunol.* **2019**, *10*, 283. [[CrossRef](#)]
164. Fonseca, M.T.; Moretti, E.H.; Marques, L.M.M.; Machado, B.F.; Brito, C.F.; Guedes, J.T.; Komegae, E.N.; Vieira, T.S.; Festuccia, W.T.; Lopes, N.P.; et al. A Leukotriene-Dependent Spleen-Liver Axis Drives TNF Production in Systemic Inflammation. *Sci. Signal.* **2021**, *14*, eabb0969. [[CrossRef](#)]

165. Dyugovskaya, L.; Polyakov, A.; Ginsberg, D.; Lavie, P.; Lavie, L. Molecular Pathways of Spontaneous and TNF- α -Mediated Neutrophil Apoptosis under Intermittent Hypoxia. *Am. J. Respir. Cell Mol. Biol.* **2011**, *45*, 154–162. [[CrossRef](#)]
166. Blaser, H.; Dostert, C.; Mak, T.W.; Brenner, D. TNF and ROS Crosstalk in Inflammation. *Trends Cell Biol.* **2016**, *26*, 249–261. [[CrossRef](#)]
167. Rieber, N.; Gazendam, R.P.; Freeman, A.F.; Hsu, A.P.; Collar, A.L.; Sugui, J.A.; Drummond, R.A.; Rongkavilit, C.; Hoffman, K.; Henderson, C.; et al. Extrapulmonary Aspergillus Infection in Patients with CARD9 Deficiency. *JCI Insight* **2016**, *1*, e89890. [[CrossRef](#)]
168. Zhang, Y.; Huang, C.; Song, Y.; Ma, Y.; Wan, Z.; Zhu, X.; Wang, X.; Li, R. Primary Cutaneous Aspergillosis in a Patient with CARD9 Deficiency and Aspergillus Susceptibility of Card9 Knockout Mice. *J. Clin. Immunol.* **2021**, *41*, 427–440. [[CrossRef](#)]
169. Ademe, M. Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges. *Front. Cell. Infect. Microbiol.* **2020**, *10*, 469. [[CrossRef](#)]
170. Zumla, A.; Rao, M.; Wallis, R.S.; Kaufmann, S.H.E.; Rustomjee, R.; Mwaba, P.; Vilaplana, C.; Yeboah-Manu, D.; Chakaya, J.; Ippolito, G.; et al. Host-Directed Therapies for Infectious Diseases: Current Status, Recent Progress, and Future Prospects. *Lancet. Infect. Dis.* **2016**, *16*, e47–e63. [[CrossRef](#)]
171. Armstrong-James, D.; Brown, G.D.; Netea, M.G.; Zelante, T.; Gresnigt, M.S.; van de Veerdonk, F.L.; Levitz, S.M. Immunotherapeutic Approaches to Treatment of Fungal Diseases. *Lancet Infect. Dis.* **2017**, *17*, e393–e402. [[CrossRef](#)]
172. Mehta, H.M.; Malandra, M.; Corey, S.J. G-CSF and GM-CSF in Neutropenia. *J. Immunol.* **2015**, *195*, 1341–1349. [[CrossRef](#)] [[PubMed](#)]
173. Damiani, G.; McCormick, T.S.; Leal, L.O.; Ghannoum, M.A. Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor Expressed in Yeast (Sargramostim): A Potential Ally to Combat Serious Infections. *Clin. Immunol.* **2020**, *210*, 108292. [[CrossRef](#)]
174. Kullberg, B.J.; Netea, M.G.; Vonk, A.G.; van der Meer, J.W. Modulation of Neutrophil Function in Host Defense against Disseminated *Candida Albicans* Infection in Mice. *FEMS Immunol. Med. Microbiol.* **1999**, *26*, 299–307. [[CrossRef](#)] [[PubMed](#)]
175. Gonzalez, C.E.; Lyman, C.A.; Lee, S.; Del Guercio, C.; Roilides, E.; Bacher, J.; Gehrt, A.; Feuerstein, E.; Tsokos, M.; Walsh, T.J. recombinant human macrophage colony-stimulating factor augments pulmonary host defences against aspergillus fumigatus. *Cytokine* **2001**, *15*, 87–95. [[CrossRef](#)] [[PubMed](#)]
176. Dongari-Bagtzoglou, A.; Kashleva, H. Granulocyte-Macrophage Colony-Stimulating Factor Responses of Oral Epithelial Cells to *Candida Albicans*. *Oral Microbiol. Immunol.* **2003**, *18*, 165–170. [[CrossRef](#)] [[PubMed](#)]
177. Gavino, C.; Cotter, A.; Lichtenstein, D.; Lejtenyi, D.; Fortin, C.; Legault, C.; Alirezaie, N.; Majewski, J.; Sheppard, D.C.; Behr, M.A.; et al. CARD9 Deficiency and Spontaneous Central Nervous System Candidiasis: Complete Clinical Remission With GM-CSF Therapy. *Clin. Infect. Dis.* **2014**, *59*, 81–84. [[CrossRef](#)]
178. Celmeli, F.; Oztoprak, N.; Turkkahraman, D.; Seyman, D.; Mutlu, E.; Frede, N.; Köksoy, S.; Grimbacher, B. Successful Granulocyte Colony-Stimulating Factor Treatment of Relapsing *Candida Albicans* Meningoencephalitis Caused by CARD9 Deficiency. *Pediatric Infect. Dis. J.* **2016**, *35*, 428–431. [[CrossRef](#)]
179. Du, B.; Shen, N.; Hu, J.; Tao, Y.; Mo, X.; Cao, Q. Complete Clinical Remission of Invasive *Candida* Infection with CARD9 Deficiency after G-CSF Treatment. *Comp. Immunol. Microbiol. Infect. Dis.* **2020**, *70*, 101417. [[CrossRef](#)]
180. Sam, Q.H.; Yew, W.S.; Seneviratne, C.J.; Chang, M.W.; Chai, L.Y.A. Immunomodulation as Therapy for Fungal Infection: Are We Closer? *Front. Microbiol.* **2018**, *9*, 1612. [[CrossRef](#)]
181. Uchida, K.; Beck, D.C.; Yamamoto, T.; Berclaz, P.-Y.; Abe, S.; Staudt, M.K.; Carey, B.C.; Filippi, M.-D.; Wert, S.E.; Denson, L.A.; et al. GM-CSF Autoantibodies and Neutrophil Dysfunction in Pulmonary Alveolar Proteinosis. *N. Engl. J. Med.* **2007**, *356*, 567–579. [[CrossRef](#)]
182. Shiomi, A.; Usui, T. Pivotal Roles of GM-CSF in Autoimmunity and Inflammation. *Mediat. Inflamm.* **2015**, *2015*, e568543. [[CrossRef](#)]
183. Cook, A.D.; Braine, E.L.; Hamilton, J.A. Stimulus-Dependent Requirement for Granulocyte-Macrophage Colony-Stimulating Factor in Inflammation. *J. Immunol.* **2004**, *173*, 4643–4651. [[CrossRef](#)]
184. Fleetwood, A.J.; Lawrence, T.; Hamilton, J.A.; Cook, A.D. Granulocyte-Macrophage Colony-Stimulating Factor (CSF) and Macrophage CSF-Dependent Macrophage Phenotypes Display Differences in Cytokine Profiles and Transcription Factor Activities: Implications for CSF Blockade in Inflammation. *J. Immunol.* **2007**, *178*, 5245–5252. [[CrossRef](#)]
185. Negoro, P.E.; Xu, S.; Dagher, Z.; Hopke, A.; Reedy, J.L.; Feldman, M.B.; Khan, N.S.; Viens, A.L.; Alexander, N.J.; Atallah, N.J.; et al. Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to *Candida* Species. *mBio* **2020**, *11*, e02043-19. [[CrossRef](#)]
186. Zajta, E.; Csonka, K.; Tóth, A.; Tiszlavicz, L.; Németh, T.; Orosz, A.; Novák, Á.; Csikós, M.; Vágvölgyi, C.; Mócsai, A.; et al. Signaling through Syk or CARD9 Mediates Species-Specific Anti-*Candida* Protection in Bone Marrow Chimeric Mice. *mBio* **2021**, *12*, e01608-21. [[CrossRef](#)]
187. Miller, Y.I.; Choi, S.-H.; Wiesner, P.; Bae, Y.S. The SYK Side of TLR4: Signalling Mechanisms in Response to LPS and Minimally Oxidized LDL. *Br. J. Pharmacol.* **2012**, *167*, 990. [[CrossRef](#)]
188. Markham, A. Fostamatinib: First Global Approval. *Drugs* **2018**, *78*, 959–963. [[CrossRef](#)]
189. Basso, V.; Garcia, A.; Tran, D.Q.; Schaal, J.B.; Tran, P.; Ngole, D.; Aqeel, Y.; Tongaonkar, P.; Ouellette, A.J.; Selsted, M.E. Fungicidal Potency and Mechanisms of θ -Defensins against Multidrug-Resistant *Candida* Species. *Antimicrob. Agents Chemother.* **2018**, *62*, e00111-18. [[CrossRef](#)]

190. Basso, V.; Tran, D.Q.; Schaal, J.B.; Tran, P.; Eriguchi, Y.; Ngole, D.; Cabebe, A.E.; Park, A.Y.; Beringer, P.M.; Ouellette, A.J.; et al. Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host Directed Mechanisms. *Sci. Rep.* **2019**, *9*, 16905. [[CrossRef](#)]
191. Tongaonkar, P.; Trinh, K.K.; Schaal, J.B.; Tran, D.; Gulko, P.S.; Ouellette, A.J.; Selsted, M.E. Rhesus Macaque θ -Defensin RTD-1 Inhibits Proinflammatory Cytokine Secretion and Gene Expression by Inhibiting the Activation of NF-KB and MAPK Pathways. *J. Leukoc. Biol.* **2015**, *98*, 1061–1070. [[CrossRef](#)]
192. Beringer, P.M.; Bensman, T.J.; Ho, H.; Agnello, M.; Denovel, N.; Nguyen, A.; Wong-Beringer, A.; She, R.; Tran, D.Q.; Moskowitz, S.M.; et al. Rhesus θ -Defensin-1 (RTD-1) Exhibits in Vitro and in Vivo Activity against Cystic Fibrosis Strains of *Pseudomonas Aeruginosa*. *J. Antimicrob. Chemother.* **2016**, *71*, 181–188. [[CrossRef](#)]
193. Bensman, T.J.; Jayne, J.G.; Sun, M.; Kimura, E.; Meinert, J.; Wang, J.C.; Schaal, J.B.; Tran, D.; Rao, A.P.; Akbari, O.; et al. Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of *Pseudomonas Aeruginosa* Lung Infection and Inflammation. *Antimicrob. Agents Chemother.* **2017**, *61*, e00154–17. [[CrossRef](#)]
194. Jayne, J.G.; Bensman, T.J.; Schaal, J.B.; Park, A.Y.J.; Kimura, E.; Tran, D.; Selsted, M.E.; Beringer, P.M. Rhesus θ -Defensin-1 Attenuates Endotoxin-Induced Acute Lung Injury by Inhibiting Proinflammatory Cytokines and Neutrophil Recruitment. *Am. J. Respir. Cell Mol. Biol.* **2018**, *58*, 310–319. [[CrossRef](#)]
195. Group, T.I.C.G.D.C.S. A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease. *N. Engl. J. Med.* **1991**, *324*, 509–516. [[CrossRef](#)]
196. Monk, E.J.M.; Harris, C.; Döffinger, R.; Hayes, G.; Denning, D.W.; Kosmidis, C. Interferon Gamma Replacement as Salvage Therapy in Chronic Pulmonary Aspergillosis: Effects on Frequency of Acute Exacerbation and All-Cause Hospital Admission. *Thorax* **2020**, *75*, 513–516. [[CrossRef](#)]
197. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Available online: <http://www.medicinescomplete.com> (accessed on 28 June 2022).
198. Stevenhagen, A.; van Furth, R. Interferon-Gamma Activates the Oxidative Killing of *Candida Albicans* by Human Granulocytes. *Clin. Exp. Immunol.* **1993**, *91*, 170–175. [[CrossRef](#)] [[PubMed](#)]
199. Schroder, K.; Hertzog, P.J.; Ravasi, T.; Hume, D.A. Interferon- γ : An Overview of Signals, Mechanisms and Functions. *J. Leukoc. Biol.* **2004**, *75*, 163–189. [[CrossRef](#)]
200. Colombo, S.A.P.; Hashad, R.; Denning, D.W.; Kumararatne, D.S.; Ceron-Gutierrez, L.; Barcenas-Morales, G.; MacDonald, A.S.; Harris, C.; Doffinger, R.; Kosmidis, C. Defective Interferon-Gamma Production Is Common in Chronic Pulmonary Aspergillosis. *J. Infect. Dis.* **2021**, *225*, jia583. [[CrossRef](#)] [[PubMed](#)]
201. Elks, P.M.; Brizee, S.; van der Vaart, M.; Walmsley, S.R.; van Eeden, F.J.; Renshaw, S.A.; Meijer, A.H. Hypoxia Inducible Factor Signaling Modulates Susceptibility to Mycobacterial Infection via a Nitric Oxide Dependent Mechanism. *PLoS Pathog.* **2013**, *9*, e1003789. [[CrossRef](#)] [[PubMed](#)]
202. Ogryzko, N.V.; Lewis, A.; Wilson, H.L.; Meijer, A.H.; Renshaw, S.A.; Elks, P.M. Hif-1 α -Induced Expression of Il-1 β Protects against Mycobacterial Infection in Zebrafish. *J. Immunol.* **2019**, *202*, 494–502. [[CrossRef](#)] [[PubMed](#)]
203. Li, C.; Wang, Y.; Li, Y.; Yu, Q.; Jin, X.; Wang, X.; Jia, A.; Hu, Y.; Han, L.; Wang, J.; et al. HIF1 α -Dependent Glycolysis Promotes Macrophage Functional Activities in Protecting against Bacterial and Fungal Infection. *Sci. Rep.* **2018**, *8*, 3603. [[CrossRef](#)]
204. Netea, M.G.; Quintin, J.; Van Der Meer, J.W. Trained immunity: A memory for innate host defense. *Cell Host Microbe* **2011**, *9*, 355–361. [[CrossRef](#)]
205. Netea, M.G.; Domínguez-Andrés, J.; Barreiro, L.B.; Chavakis, T.; Divangahi, M.; Fuchs, E.; Joosten, L.A.; van der Meer, J.W.; Mhlanga, M.M.; Mulder, W.J.; et al. Defining trained immunity and its role in health and disease. *Nat. Rev. Immunol.* **2020**, *20*, 375–388. [[CrossRef](#)]
206. Quintin, J.; Saeed, S.; Martens, J.H.; Giamarellos-Bourboulis, E.J.; Ifrim, D.C.; Logie, C.; Jacobs, L.; Jansen, T.; Kullberg, B.J.; Wijmenga, C.; et al. *Candida albicans* infection affords protection against reinfection via functional reprogramming of monocytes. *Cell Host Microbe* **2012**, *12*, 223–232. [[CrossRef](#)]
207. Lilly, E.A.; Yano, J.; Esher, S.K.; Hardie, E.; Fidel, P.L., Jr.; Noverr, M.C. Spectrum of trained innate immunity induced by low-virulence *Candida* species against lethal polymicrobial intra-abdominal infection. *Infect. Immun.* **2019**, *87*, e00348–19. [[CrossRef](#)]
208. Lilly, E.A.; Bender, B.E.; Esher Righi, S.; Fidel, P.L., Jr.; Noverr, M.C. Trained Innate Immunity Induced by Vaccination with Low-Virulence *Candida* Species Mediates Protection against Several Forms of Fungal Sepsis via Ly6G+ Gr-1+ Leukocytes. *mBio* **2021**, *12*, e0254821. [[CrossRef](#)]
209. Quintin, J. Fungal mediated innate immune memory, what have we learned? *Semin. Cell Dev. Biol.* **2019**, *89*, 71–77. [[CrossRef](#)]